0001654954-17-004568.txt : 20170512 0001654954-17-004568.hdr.sgml : 20170512 20170512154028 ACCESSION NUMBER: 0001654954-17-004568 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170512 DATE AS OF CHANGE: 20170512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52898 FILM NUMBER: 17838314 BUSINESS ADDRESS: STREET 1: 469 JEAN-TALON WEST STREET 2: 3RD FLOOR CITY: MONTREAL STATE: A8 ZIP: H3N 1R4 BUSINESS PHONE: 514-764-9698 MAIL ADDRESS: STREET 1: 469 JEAN-TALON WEST STREET 2: 3RD FLOOR CITY: MONTREAL STATE: A8 ZIP: H3N 1R4 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 10-Q 1 sbfm_10q.htm QUARTERLY REPORT Blueprint
 

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
Form 10-Q
 
Quarterly Report Under
the Securities Exchange Act of 1934
 
For Quarter Ended: March 31, 2017
 
Commission File Number: 000-52898
 
SUNSHINE BIOPHARMA INC.
(Exact name of small business issuer as specified in its charter)
 
Colorado
 
20-5566275
(State of other jurisdiction of incorporation)
 
(IRS Employer ID No.)
 
469 Jean-Talon West
3rd Floor
Montreal, Quebec, Canada H3N 1R4
(Address of principal executive offices)
 
(514) 764-9698
(Issuer’s Telephone Number)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☑  No ☐
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)
 
 
Large accelerated filer  ☐
Accelerated filer  ☐
 
Non-accelerated filer  ☐
Smaller reporting company  ☐
 
Emerging growth company ☒
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No
 
The number of shares of the registrant’s only class of common stock issued and outstanding as of May 12, 2017, was 858,594,650 shares.
 

 
 
 
TABLE OF CONTENTS
 
 
 
 
PART I.
FINANCIAL INFORMATION
 
Page No.
 
 
 
 
 
 
 
Item 1.
 
Financial Statements
 
 
3
 
 
 
Unaudited Consolidated Balance Sheet as of March 31, 2017
 
 
3
 
 
 
Unaudited Consolidated Statement of Operations for the Three Month Periods Ended March 31, 2017 and 2016
 
 
4
 
 
 
Unaudited Consolidated Statement of Cash Flows for the for the Three Month Periods Ended March 31, 2017 and 2016
 
 
5
 
 
 
Notes to Consolidated Financial Statements
 
 
6
 
Item 2.
 
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
 
13
 
Item 3.
 
Quantitative and Qualitative Disclosures About Market Risk.
 
 
18
 
Item 4.
 
Controls and Procedures.
 
 
18
 
 
 
 
 
 
 
 
 
 
PART II
 
 
 
 
 
 
OTHER INFORMATION
 
 
 
 
 
 
 
 
 
 
 
Item 1.
 
Legal Proceedings
 
 
19
 
Item 1A.
 
Risk Factors
 
 
19
 
Item 2.
 
Unregistered Sales of Equity Securities and Use of Proceeds
 
 
19
 
Item 3.
 
Defaults Upon Senior Securities
 
 
20
 
Item 4.
 
Mine Safety Disclosures
 
 
20
 
Item 5.
 
Other Information
 
 
20
 
Item 6.
 
Exhibits
 
 
20
 
 
 
 
Signatures
 
 
21
 
 
 
2
 
 
Sunshine Biopharma, Inc.
 
 
 
 
 
 
Unaudited Consolidated Balance Sheet
 
 
 
 
 
 
           
 
 
Unaudited
 
 
Audited
 
 
 
March 31,
 
 
December 31,
 
 
 
2017
 
 
2016
 
ASSETS
 
 
 
 
 
 
 
 
 
 
 
 
 
Current Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and cash equivalents
 $17,143 
 $57,453 
Prepaid expenses
  846 
  1,007 
 
    
    
Total Current Assets
  17,989 
  58,460 
 
    
    
Equipment (net of $2,797 and $2,272 depreciation, resepctively)
  5,420 
  5,944 
Patents (net of $58,918 amortization and $556,120 impairment)
    -
  -
 
    
    
TOTAL ASSETS
 $23,409 
 $64,404 
 
    
    
 
    
    
 
    
    
LIABILITIES AND SHAREHOLDERS' EQUITY
    
    
 
    
    
Current liabilities:
    
    
 
    
    
Current portion of notes payable
  71,439 
  69,939 
Current portion of notes payable - related party
  183,889 
  167,032 
Accounts payable
  27,953 
  28,122 
Interest payable
  1,171 
  9,011 
 
    
    
Total current liabilities
  284,452 
  274,104 
 
    
    
TOTAL LIABILITIES
  284,452 
  274,104 
 
    
    
COMMITMENTS AND CONTINGENCIES
    
    
 
    
    
SHAREHOLDERS' EQUITY (DEFICIT)
    
    
 
    
    
Preferred stock, Series A $0.10 par value per share;
    
    
 Authorized 850,000 Shares; Issued
    
    
 and outstanding -0- shares.
  - 
  - 
 
    
    
Preferred stock, Series B $0.10 par value per share;
    
    
 Authorized 500,000 Shares; Issued
    
    
 and outstanding 500,000 shares.
  50,000 
  50,000 
 
    
    
Common Stock, $0.001 par value per share;
    
    
 Authorized 3,000,000,000 Shares; Issued
    
    
 and outstanding 817,927,983 and 769,399,858 at
    
    
 March 31, 2017 and December 31, 2016, respectively
  817,928 
  769,400 
 Reserved for issuance 204,918,033 at March 31, 2017
    
    
Capital paid in excess of par value
  11,642,783
  11,548,460 
 
    
    
Accumulated comprehensive income
  1,903 
  394 
 
    
    
Accumulated (Deficit)
  (12,773,657)
  (12,577,954)
 
    
    
TOTAL SHAREHOLDERS' EQUITY (DEFICIT)
  (261,043)
  (209,700)
 
    
    
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
 $23,409 
 $64,404 
 
 
See Accompanying Notes To These Financial Statements.
 
 
3
 
 
Sunshine Biopharma, Inc.
 
 
Unaudited Consolidated Statement Of Operations and Comprehensive Loss
 
 
 
 
 
 
 
Unaudited
 
 
Unaudited
 
 
 
3 Months
 
 
3 Months
 
 
 
Ended
 
 
Ended
 
 
 
March 31,
 
 
March 31,
 
 
 
2017
 
 
2016
 
 
 
 
 
 
 
 
Revenue:
 $- 
 $- 
 
    
    
General & Administrative Expenses
    
    
 
    
    
Accounting
  15,600 
  6,800 
Amortization & depreciation
  518 
  15,244 
Consulting
  25,937
  14,184 
Legal
  14,904 
  28,099 
Office
  7,401 
  3,269 
Officer & director remuneration
  42,965 
  - 
Stock transfer fee
  1,665 
  2,086 
 
    
    
Total G & A
  108,990
  69,682 
 
    
    
(Loss) from operations
  (108,990)
  (69,682)
 
    
    
Other Income (expense):
    
    
Foreign exchange gain
  (639)
  - 
Interest expense
  (9,144)
  (6,954)
Litigation settlement proceeds
  - 
  25,000 
Loss on debt conversions
  (76,929)
  (253,658)
 
    
    
Total Other (Expense)
  (86,712)
  (235,612)
 
    
    
     Net (loss)
 $(195,702)
 $(305,294)
 
    
    
Basic (Loss) per common share
 $0.00 
 $0.00 
 
    
    
Weighted Average Common Shares Outstanding
  805,604,089 
  215,596,040 
 
    
    
Net Income (Loss)
 $(195,702)
 $(305,294)
Other comprehensive income:
    
    
Unrealized Gain (Loss) from foreign exchange translation
  1,509 
  (9,991)
Comprehensive (Loss)
  (194,193)
  (315,285)
 
    
    
Basic (Loss) per common share
 $0.00 
 $0.00 
 
    
    
Weighted Average Common Shares Outstanding
  805,604,089 
  215,596,040 
 
 See Accompanying Notes To These Financial Statements.
 
 
4
 
 
Sunshine Biopharma, Inc.
 
 
 
 
Unaudited Consolidated Statement Of Cash Flows
 
 
     
 
 
 
Unaudited
 
 
Unaudited
 
 
 
3 Months
 
 
3 Months
 
 
 
Ended
 
 
Ended
 
 
 
March 31,
 
 
March 31,
 
 
 
2017
 
 
2016
 
Cash Flows From Operating Activities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net (Loss)
 $(195,702)
 $(305,294)
 
    
    
Adjustments to reconcile net loss to net cash used in
    
    
 operating activities:
    
    
 
    
    
Foreign exchange loss
  639 
    
Depreciation/Amortization
 525
  15,244 
Stock issued for payment interest
  3,022 
  3,120 
Loss on debt conversion
  76,929 
  253,658 
Stock issued for payment of expenses
  14,400
  - 
(Increase) decrease in prepaid expenses
  161 
  (44)
Increase (decrease) in Accounts Payable & accrued expenses
  (171)
  (52,116)
Increase (decrease) in interest payable
  (7,840)
  3,834 
 
    
    
Net Cash Flows (used) in operations
  (108,037)
  (81,598)
 
    
    
Cash Flows From Investing Activities:
    
    
 
    
    
 
    
    
Purchase of equipment
  - 
  - 
 
    
    
Net Cash Flows (used) in Investing activities
  - 
  - 
 
    
    
Cash Flows From Financing Activities:
    
    
 
    
    
Proceed from note payable
  50,256 
  82,000 
Note payable used to pay expenses
  13,962 
  - 
Note payable used to pay origionation fees & interest
  2,000 
  3,000 
Sale of common stock
  - 
  79,128 
 
    
    
Net Cash Flows provided by financing activities
  66,218 
  164,128 
 
    
    
 
    
    
Net Increase (Decrease) In Cash and cash equivalents
  (41,819)
  82,530 
Foreign currency translation adjustment
  1,509 
  (9,991)
Cash and cash equivalents at beginning of period
  57,453 
  50,798 
 
    
    
Cash and cash equivalents at end of period
 $17,143 
 $123,337 
 
    
    
Supplementary Disclosure Of Cash Flow Information:
    
    
 
    
    
Stock issued for services, licenses and other assets
 $14,400 
 $100,000 
Stock issued for note conversions including interest
 $128,451
 $377,814 
Cash paid for interest
 $- 
 $- 
Cash paid for income taxes
 $- 
 $- 
 
 See Accompanying Notes To These Financial Statements.
 
 
5
 
 
Sunshine Biopharma, Inc.
Notes To Unaudited Consolidated Financial Statements
For The Three Month Interim Period Ended March 31, 2017
 
Note 1 – Description of Business
 
Mountain West Business Solutions, Inc. (“MWBS”) was incorporated on August 31, 2006 in the State of Colorado. Sunshine Etopo, Inc. (formerly Sunshine Biopharma, Inc.) was incorporated in the State of Colorado on August 17, 2009. Effective October 15, 2009, MWBS was acquired by Sunshine Etopo, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its name to Sunshine Biopharma, Inc. Sunshine Etopo, Inc. has been inactive and was recently dissolved. In July 2014, the Company formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. The financial statements represent the consolidated activity of Sunshine Biopharma, Inc. and Sunshine Biopharma Canada Inc. (hereinafter together referred to as the "Company"). The Company was formed for the purposes of conducting research, development and commercialization of drugs for the treatment of various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board of Directors of the Company.
 
The Company’s wholly owned Canadian Subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”) was formed for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. Sunshine Canada has recently signed licensing agreements for four (4) generic prescription drugs for treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia). In addition, Sunshine Canada is currently evaluating several other generic products for in-licensing and is working on securing a Drug Establishment License (“DEL”) and a Drug Identification Number (“DIN”) per product from Health Canada. Once the DEL and the DIN’s are secured, Sunshine Canada will begin its generic pharmaceuticals marketing and sales program in Canada and overseas.
 
In addition, the Company has been and continues to work on the development of its proprietary anticancer drug, Adva-27a. The next series of steps in the development of Adva-27a include (i) GMP-manufacturing of a 2-kilogram quantity of the drug, (ii) completing requisite IND-enabling studies, and (iii) conducting Phase I clinical trials. In the preclinical studies, Adva-27a was shown to be effective at destroying multidrug resistant cancer cells including Pancreatic Cancer, Breast Cancer, Lung Cancer and Uterine Sarcoma, cells.
 
During the last three month period the Company has continued to raise money through stock sales and borrowings.
 
The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s generics business and proprietary drug development program.
 
Note 2 – Summary of Significant Accounting Policies
 
See the Notes in the 2016 Form 10-K consolidated financial statements for a complete summary of the Company’s significant accounting policies.
 
This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements.
 
 
6
 
 
Sunshine Biopharma, Inc.
Notes To Unaudited Consolidated Financial Statements
For The Three Month Interim Period Ended March 31, 2017
 
PRINCIPLES OF CONSOLIDATION
 
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
 
USE OF ESTIMATES
 
The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.
 
CASH AND CASH EQUIVALENTS
 
For the Balance Sheets and Statement of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $17,143 and $57,453 as of March 31, 2017 and December 31, 2016, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000.
 
EARNINGS PER SHARE
 
The Company has adopted the FASB ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.
 
Other than the Notes Payable specified under Note 4 and Note 5 below, there were no potentially dilutive instruments outstanding during the interim period ended March 31, 2017 or the year ended December 31, 2016.
 
INCOME TAXES
 
The Company follows the asset and liability method of accounting for deferred income taxes. The asset and liability method requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between financial accounting and tax bases of assets and liabilities. The Company accounts for income taxes pursuant to ASC 740. There was no increase in liabilities for unrecognized tax benefits as a result of this implementation. The Company recognizes accrued interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expense.
 
 
7
 
 
Sunshine Biopharma, Inc.
Notes To Unaudited Consolidated Financial Statements
For The Three Month Interim Period Ended March 31, 2017
 
FUNCTIONAL CURRENCY
 
The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar. The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:
 
●
Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.
 
●
Income statement accounts are translated using the weighted average exchange rate for the period.
 
The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.
 
REVENUE RECOGNITION
 
Since inception, the Company has been focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Following its recent entry into the generic pharmaceuticals business, the Company has become a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications. The Company intends to recognize revenues from the sales of generic pharmaceuticals, if or when they occur, at the time the products are sold and collectability is assured. In the event the Company provides consulting services in the future, revenues from such services will be recognized when the services are rendered and invoiced.
 
GOING CONCERN
 
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Since inception, the Company has had recurring operating losses and negative operating cash flows. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
 
The Company’s continuation as a going concern is dependent on its ability to obtain additional financing to fund operations, implement its business model, and ultimately, attain profitable operations. The Company will need to secure additional funds through various means, including equity and debt financing or any similar financing. There can be no assurance that the Company will be able to obtain additional equity or debt financing, if and when needed, on terms acceptable to the Company, or at all. Any additional equity or debt financing may involve substantial dilution to the Company’s stockholders, restrictive covenants or high interest costs. The Company’s long-term liquidity also depends upon its ability to generate revenues and achieve profitability.
 
The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
 
 
8
 
 
Sunshine Biopharma, Inc.
Notes To Unaudited Consolidated Financial Statements
For The Three Month Interim Period Ended March 31, 2017 

Note 3 – Unaudited Financial Information
 
The unaudited financial information included for the three month interim period ended March 31, 2017 was taken from the books and records of the Company without audit. However, such information reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to reflect properly the results of the interim periods presented. The results of operations for the three month interim period ended March 31, 2017 are not necessarily indicative of the results expected for the fiscal year ending December 31, 2017.
 
Note 4 – Notes Payable
 
A Note Payable having a face value of $21,439 and a maturity date of December 31, 2017 was entered into on December 31, 2016. This Note accrues interest at a rate of 12% per annum and is convertible after December 31, 2016 into $0.001 par value Common Stock at a price 35% below market value. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.
 
A Note payable dated July 1, 2016, having a face value of $55,000 and a principal balance of $48,500 at December 31, 2016, accrued interest at 10%. This note was convertible into $0.001 par value Common Stock at a price 40% below market value. During the three month period ended March 31, 2017, a total of $48,500 in principal and $3,022 of interest was converted into $0.001 par value Common Stock leaving a principal balance of $-0-. In connection with this conversion, 42,528,125 shares of $0.001 par value Common Stock valued at $128,451 were issued generating a loss of $76,929 on conversion.
 
On February 10, 2017, the Company received net proceeds of $48,000 in exchange for a note payable having a face value of $50,000 and accruing interest at the rate of 8% per annum. The note, due on November 20, 2017, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 39% below market value. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. In connection with this note, 204,918,033 shares of the Company's Common Stock have been reserved for issuance.
 
At March 31, 2017 and December 31, 2016, accrued interest on Notes Payable was $15,124 and $9,011, respectively.
 
 
9
 
 
Sunshine Biopharma, Inc.
Notes To Unaudited Consolidated Financial Statements
For The Three Month Interim Period Ended March 31, 2017

Note 5 – Notes Payable Related Party
 
In December 2016, the Company received monies from its CEO in exchange for a note payable having a principal amount of $90,000 Canadian ($67,032 US) ’–with interest at 12% due March 31, 2017. The note is convertible any time after the date of issuance into $0.001 par value Common Stock at a price 35% below market value. The Company estimated that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. This note is collateralized by all of the assets of the Company. In the event of default, the interest rate will increased to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note, together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US) paid to the Company on March 28, 2017, was renewed for a 90-day period under the same terms and conditions as the original note. The new note now having a face value of $96,021 Canadian ($72,198 US) is due on June 30, 2017.
 
A note payable held by a private individual who became a principal shareholder of the Company having a face value of $100,000 at December 31, 2016 and a maturity date of March 31, 2017, accrues interest at 12%. The Note is convertible any time from the date of issuance into $0.001 par value Common Stock at a 35% discount from market price. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. On March 31, 2017, the note’s principal balance of $100,000 plus accrued interest of $11,715 was renewed for a period of 90-day under the same terms and conditions as the original note. The new note now having a face value of $111,715 matures on June 30, 2017.
 
Note 6 – Issuance of Common Stock
 
During the three months ended March 31, 2017, the Company issued a total of 48,428,125 shares of $0.001 par value Common Stock. Of these 42,428,125 shares valued at $128,451 were issued upon conversion of outstanding notes payable, reducing the debt by $48,500 and interest payable by $3,022 and generating a loss on conversion of $76,929.
 
In addition, the Company issued 6,000,000 shares of $0.001 par value Common Stock valued at $14,400 for $15,000 Canadian ($11,278 US). The $15,000 Canadian was paid directly to a firm which was engaged to conduct a valuation of the Company’s patents. The difference of $3,122 was recorded as a consulting expense.
 
In connection with its convertible notes payable, the Company has 204,918,033 shares of its Common Stock reserved for issuance at March 31,2017.
 
The Company declared no dividends through March 31, 2017.
 
 
10
 
 
Sunshine Biopharma, Inc.
Notes To Unaudited Consolidated Financial Statements
For The Three Month Interim Period Ended March 31, 2017
 
Note 7 – Earnings (Loss) Per Share
 
Earnings (loss) per share is computed using the weighted average number of Common Shares outstanding during the period. The Company has adopted ASC 260 (formerly SFAS128), “Earnings per Share”.
 
Note 8 -- Generic Drugs Licenses
 
In 2016, the Company entered into License Agreements for the following four Generic Drugs:
 
●
Anastrozole (brand name Arimidex® by AstraZenica) for treatment of Breast Cancer
●
Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer
●
Bicalutamide (brand name Casodex® by AstraZenica) for treatment of Prostate Cancer
●
Finasteride (brand name Propecia® by Merck) for treatment of Benign Prostatic Hyperplasia
 
The cost of these Licenses has been fully expensed.
 
Note 9 – Financial Statements
 
For a complete set of footnotes, reference is made to the Company’s Report on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission and the audited financial statements and notes included therein.
 
Note 10 – Income Taxes
 
Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. Loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.
 
A deferred tax asset at each date has been offset by a 100% valuation allowance.
 
Note 11 – Royalties Payable
 
As part of a subscription agreement entered into in 2016, the Company has an obligation to pay a royalty of 5% of net sales on one of its generic products (Anastrozole) for a period of three (3) years from the date of the first sale of that product.
 
Note 12 – Related Party Transactions
 
In addition to the related party transactions detailed in Note 5 above, during the three month period ended March 31, 2017, the Company paid its Officers and Directors cash compensation totaling $42,965. $1,519 was paid to the Company’s COO and $41,446 was paid to the Company’s CEO.
 
During the fiscal year ended December 31, 2016, Advanomics Corporation paid on behalf of the Company $13,725 Canadian in patenting fees. Advanomics was fully reimbursed by the Company in January 2017.
 
 
11
 
 
Sunshine Biopharma, Inc.
Notes To Unaudited Consolidated Financial Statements
For The Three Month Interim Period Ended March 31, 2017
 
Note 13 – Subsequent Events
 
In April 2017, the Company received monies in exchange for a convertible note payable having a face value of $100,000 Canadian (approximately $75,190 US).
 
On April 3, 2017, the Company sold 34,000,000 shares of its $0.001 par value Common Stock valued at $98,600 for $85,000 Canadian (approximately $63,912 US).
 
On April 24, 2017, the Company issued 6,666,667 shares of its $0.001 par value Common Stock for the purchase of laboratory equipment valued at $22,000.
 
On April 26, 2017, the Company received monies in exchange for a convertible note payable having a face value of $65,000. In connection with this note, 100,000,000 shares of the Company's Common Stock have been reserved for issuance.
 
 
12
 
 
PART I.
 
ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.
 
Overview and History
 
We were incorporated in the State of Colorado on August 31, 2006 under the name “Mountain West Business Solutions, Inc.”  Until October 2009, our business was to provide management consulting with regard to accounting, computer and general business issues for small and home-office based companies. Effective October 15, 2009, we executed an agreement to acquire Sunshine Biopharma, Inc., a Colorado corporation, in exchange for the issuance of 21,962,000 shares of our Common Stock and 850,000 shares of Convertible Preferred Stock, each convertible into twenty (20) shares of our Common Stock. As a result of this transaction we changed our name to “Sunshine Biopharma, Inc. and our officers and directors resigned their positions with us and were replaced by our current management. The majority of the Common Shares and all of the Convertible Preferred Shares we issued for this transaction were issued to Advanomics Corporation, a privately held Canadian company (“Advanomics”). On December 21, 2011, Advanomics exercised its right to convert the 850,000 shares of Series “A” Preferred Stock it held in our Company into 17,000,000 shares of Common Stock.  
 
Following the above detailed transactions, we began to operate as a pharmaceutical company focusing on development of the Adva-27a anticancer compound. We operated under a the exclusive technology license agreement with Advanomics until December 2015, at which time we acquired all of the worldwide right to the technology and became direct owner of all issued and pending patents pertaining to the Adva-27a technology. Following acquisition of the Adva-27a patents, the exclusive license agreement with Advanomics was terminated and Sunshine Etopo, Inc., Sunshine Biopharma Inc.’s subsidiary holding the exclusive license with Advanomics, was dissolved.
 
In July 2014, we formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”), for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the globe. Sunshine Canada has recently signed licensing agreements for four (4) generic prescription drugs for the treatment of cancer and BPH (Benign Prostatic Hyperplasia). With our entry into the generic pharmaceuticals business, we have become a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications.
 
Our principal place of business is located at 469 Jean-Talon West, 3rd Floor, Montreal, Quebec, Canada H3N 1R4.  Our phone number is (514) 764-9698 and our website address is www.sunshinebiopharma.com.
 
We have not been subject to any bankruptcy, receivership or similar proceeding.
 
Results Of Operations
 
Comparison of Results of Operations for the three months ended March 31, 2017 and 2016
 
For the three months ended March 31, 2017 and 2016, we did not generate any revenues.
 
General and administrative expenses during the three month period ended March 31, 2017 were $108,990, compared to general and administrative expense of $69,682 incurred during the three month period ended March 31, 2016, an increase of $39,308. This increase is primarily attributable to an increase of approximately $43,000 in executive compensation. We also incurred increased accounting and consulting fees, but lower legal fees during the three months ended March 31, 2017, compared to the similar period in 2016.  Most of our other expenses remained relatively constant during the three month period ended March 31, 2017 compared to the similar period in 2016.  We also incurred $9,144 in interest expense during the three months ended March 31, 2017, compared to $6,954 in interest expense during the similar period in 2016 as a result of decreased borrowings.  However, we incurred $76,929 in losses arising from debt conversion during the three months ended March 31, 2017, compared to $253,658 in losses from debt conversion during the similar period in 2016, a difference of $176,729 as a result of a smaller amount of convertible notes outstanding. We also received $25,000 from the settlement of litigation in 2016 that we did not receive during the three months ended March 31, 2017.
 
As a result, we incurred a net loss of $195,702 ($0.00 per share) for the three month period ended March 31, 2017, compared to a net loss of $305,294 ($0.00 per share) during the three month period ended March 31, 2016.
 
Because we did not generate any revenues since our inception, following is our Plan of Operation.
 
 
13
 
 
Plan of Operation
 
Since inception, we have been operating as a pharmaceutical company focused on the research, development and commercialization of proprietary drugs for the treatment of various forms of cancer.  In July 2014, we formed Sunshine Biopharma Canada Inc., a Canadian wholly owned subsidiary, for the purposes of conducting generic pharmaceuticals business in Canada and elsewhere around the world. During 2016, we intensified our activities in the generic pharmaceuticals area as we continued to pursue our proprietary anticancer drug development efforts. Accordingly, we have become a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications. Below we describe our Generic Pharmaceuticals Operations followed by our Proprietary Drug Development Program.
 
Generic Pharmaceuticals Operations
 
In 2016, our Canadian wholly owned subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”), signed Cross Referencing Agreements with a major pharmaceutical company for four prescription generic drugs for the treatment of Breast Cancer, Prostate Cancer and Enlarged Prostate. We will market and sell these new pharmaceutical products under our own Sunshine Biopharma label. These four generic products are as follows:
 
●
Anastrozole (brand name Arimidex® by AstraZeneca) for treatment of Breast Cancer;
●
Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer;
●
Bicalutamide (brand name Casodex® by AstraZenica) for treatment of Prostate Cancer;
●
Finasteride (brand name Propecia® by Merck) for treatment of BPH (Benign Prostatic Hyperplasia) 
 
Worldwide sales of the brand name version of these products as reported in the SEC filing of the respective owner of the registered trademark are as follows:
 
●
Arimidex® $232M in 2016
●
Femara® $380M in 2014
●
Casodex® $247M in 2016
●
Propecia® $183M in 2015
 
Sunshine Canada is currently in the process of securing a Drug Identification Number (“DIN”) for each of these products from Health Canada. We are also working on finding an appropriate facility and obtaining a Drug Establishment License (“DEL”) from Health Canada. Upon receipt of the DEL and DIN’s, we will be able to accept orders for our own label SBI-Anastrozole, SBI-Letrozole, SBI-Bicalutamide and SBI-Finasteride. We cannot estimate the timing in our obtaining either the DIN or DEL due to variables involved that are out of our control. The Figure below shows our 30-Pill blister pack of Anastrozole.
 
 
We currently have twenty three (23) additional Generic Pharmaceuticals under review for in-licensing. While no assurances can be provided, when completed, this will bring our Generic Products portfolio to a total of twenty seven (27). We believe that a larger product portfolio provides us with more opportunities and a greater reach into the marketplace. We hope to further build our generics portfolio of “SBI” label Generic Pharmaceuticals over time.
 
Various publicly available sources indicate that the worldwide sales of generic pharmaceuticals are approximately $200 billion per year. In the United States and Canada, the sales of generic pharmaceuticals are approximately $50 billion and $5 billion, respectively. The generic pharmaceuticals business is fairly competitive and there are several multinational players in the field including Teva (Israel), Novartis - Sandoz (Switzerland), Hospira (USA), Mylan (Netherlands), Sanofi (France), Fresenius Kabi (Germany) and Apotex (Canada). While no assurances can be provided, with our offering of Canadian approved products we believe that we will be able to access at least a small percentage of the generic pharmaceuticals marketplace.
 
As part of a subscription agreement, we have an obligation to pay a royalty of 5% of net sales on one of our generic products (Anastrozole) for a period of three (3) years from the date of the first sale of that product.
 
While no assurances can be provided and subject to the availability of adequate financing, of which there is no assurance, we anticipate that profits from the sales of Generic Products will be used to finance our proprietary drug development program, including Adva-27a, our flagship anticancer compound. In addition to near-term revenue generation, building the generics business infrastructure and securing the proper permits will render us appropriately positioned for the marketing and distribution of our proprietary Adva-27a drug candidate, provided that Adva-27a is approved for such marketing and distribution, of which there can be no assurance.
 
 
14
 
Proprietary Drug Development Operations
 
Our proprietary drug development activities have been focused on the development of a small molecule called Adva-27a for the treatment of aggressive cancers. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patent Number 8,236,935. See “Part I, Item 1 – Business - Intellectual Property.”
 
Summary of Adva-27a Preclinical Studies
 
Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin. Another derivative of Podophyllotoxin called Etoposide is currently on the market and is used to treat various types of cancer including leukemia, lymphoma, testicular cancer, lung cancer, brain cancer, prostate cancer, bladder cancer, colon cancer, ovarian cancer, liver cancer and several other forms of cancer. Etoposide is one of the most widely used anticancer drugs. Adva-27a and Etoposide are similar in that they both attack the same target in cancer cells, namely the DNA unwinding enzyme, Topoisomerase II. Unlike Etoposide, and other anti-tumor drugs currently in use, Adva-27a is able to destroy Multidrug Resistant Cancer cells. Adva-27a is the only compound known today that is capable of destroying Multidrug Resistant Cancer. In addition, Adva-27a has been shown to have distinct and more desirable biological and pharmacological properties compared to Etoposide. In side-by-side studies using Multidrug Resistant Breast Cancer cells and Etoposide as a reference, Adva-27a showed markedly improved cell killing activity (see Figure below). Our preclinical studies to date have shown that:
 
●
Adva-27a is effective at killing different types of Multidrug Resistant cancer cells, including Pancreatic Cancer Cells (Panc-1), Breast Cancer Cells (MCF-7/MDR), Small-Cell Lung Cancer Cells (H69AR), and Uterine Sarcoma Cells (MES-SA/Dx5).
 
●
Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
 
●
Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.
 
●
Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
 
●
Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar (this number has recently been reduce to 1.44 micromolar as a result of resolving the two isomeric forms of Adva-27a).
 
●
Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.
 
●
Adva-27a does not inhibit tubulin assembly.
 
These and other preclinical data have been published in ANTICANCER RESEARCH, a peer-reviewed International Journal of Cancer Research and Treatment. The publication which is entitled “Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective Against Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH 32: 4423-4432 (2012)] is available on our website at www.sunshinebiopharma.com.
 
 
15
 
 
Clinical Development Path
 
The early stage preclinical studies for our lead compound, Adva-27a, were successfully completed and the results have been published in ANTICANCER RESEARCH 32: 4423-4432 (2012). We have been delayed in our implementation of our clinical development program due to lack of funding. Our fund raising efforts are continuing and as soon as adequate financing is in place we will continue our clinical development program of Adva-27a by conducting the next sequence of steps comprised of the following:
 
●
GMP Manufacturing of 2 kilogram for use in IND-Enabling Studies and Phase I Clinical Trials
●
IND-Enabling Studies
●
Regulatory Filing (Fast-Track Status Anticipated)
●
Phase I Clinical Trials (Pancreatic Cancer and in parallel Multidrug Resistant Breast Cancer)
 
 GMP Manufacturing
 
In November 2014, we entered into a Manufacturing Services Agreement with Lonza Ltd. and Lonza Sales Ltd. (hereinafter jointly referred to as “Lonza”), whereby we engaged Lonza to be the manufacturer of our Adva-27a anticancer drug. In June 2015 we received a sample of the pilot manufacturing run for evaluation. Our laboratory analyses showed that, while the sample meets the required biological specifications, the amount of material generated (the “Yield”) by the pilot run was found to be significantly lower than planned. During the course of our discussions concerning the problem of the low Yield, Lonza informed us that they required us to pay them $687,818 prior to moving forward with any activity pertaining to the manufacturing agreement we have with them. We have repeatedly indicated to Lonza that a clear path defining exactly how the extremely low Yield issue would be addressed is imperative prior to us making any payments. As of the date of this report, neither party has changed its position. See “Part I, Item 3 – Legal Proceedings.”
 
Clinical Trials
 
Adva-27a’s initial indication will be pancreatic cancer for which there are currently little or no treatment options available. We have concluded an agreement with McGill University’s Jewish General Hospital in Montreal, Canada to conduct Phase I clinical trials for this indication. All aspects of the planned clinical trials in Canada will employ FDA standards at all levels. Subject to obtaining the necessary financing, we now anticipate that Phase I clinical trials will commence in mid-2018 and we estimate that it will take 18 months to complete, at which time we expect to receive limited marketing approval for “compassionate-use” under the FDA and similar guidelines in Canada. See “Potential Near-Term Opportunities” below.
 
Potential Near-Term Opportunities
 
According to the American Cancer Society, nearly 1.5 million new cases of cancer are diagnosed in the U.S. each year.  Given the terminal and limited treatment options available for the pancreatic cancer indication we are planning to study, we anticipate being granted limited marketing approval (“compassionate-use”) for our Adva-27a following receipt of funding and a successful Phase I clinical trial.  There are no assurances that either will occur.  Such limited approval will allow us to make the drug available to various hospitals and health care centers for experimental therapy and/or “compassionate-use”, thereby generating revenues in the near-term.
 
In addition, we believe that upon successful completion of Phase I Clinical Trials we may receive one or more offers from large pharmaceutical companies to buyout or license our drug at a significant premium.  However, there are no assurances that our Phase I Trials will be successful, or if successful, that any pharmaceutical companies will make an acceptable offer to us.  In the event we do not consummate such a transaction, we will require significant capital in order to complete the requisite additional clinical trials towards a potential full marketing approval, of which there can be no assurance.
 
 
 A Space-Filling Model of Our Anticancer Compound, Adva-27a
 
16
 
 
Intellectual Property
 
Effective October 8, 2015, we executed a Patent Purchase Agreement (the “October Purchase Agreement”), with Advanomics, a related party, pursuant to which we acquired all of the right, title and interest in and to U.S. Patent Number 8,236,935 (the “US Patent”) for our anticancer compound, Adva-27a.  On December 28, 2015, we executed a second Patent Purchase Agreement (the “December Purchase Agreement”), with Advanomics, pursuant to which we acquired all of the right, title and interest in and to all of the remaining worldwide rights covered by issued and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 (the “Worldwide Patents”) for our anticancer compound, Adva-27a.
 
Effective December 28, 2015, we entered into amendments (the “Amendments”) of these Purchase Agreements pursuant to which the total purchase price was reduced from $17,142,499 to $618,810, the book value of this intellectual property on the financial statements of Advanomics.  Further, the Amendments provided for automatic conversion of the promissory notes representing the new purchase price into an aggregate of 321,305,415 shares of our Common Stock once we increase our authorized capital such that these shares can be issued.  In July 2016 we increased our authorized capital and issued the 321,305,415 Common shares to Advanomics thereby completing all aspects of the patent purchase arrangements and securing direct ownership of all worldwide patents and rights pertaining to Adva-27a.
 
In addition, in 2016 we signed Cross Referencing Agreements with a major pharmaceutical company for four (4) prescription generic drugs for the treatment of Breast Cancer, Prostate Cancer and Enlarged Prostate. These agreements give us the right to register the four (4) generic products, Anastrozole, Letrozole, Bicalutamide and Finasteride in Canada under our own label and obtain a DIN for each in order to be able to place them on the market.
 
While no assurances can be provided, we are also planning to expand our product line through acquisitions and/or in-licensing as well as in-house research and development.
 
Liquidity and Capital Resources
 
As of March 31, 2017, we had cash or cash equivalents of $17,143.
 
Net cash used in operating activities was $108,037 during the three month period ended March 31, 2017, compared to $81,598 for the three month period ended March 31, 2016.  We anticipate that overhead costs and other expenses will increase in the future as we move forward with our proprietary drug development activities and our efforts to become a fully integrated pharmaceutical company by offering generic pharmaceutical products as discussed above.
 
Cash flows from financing activities were $66,218 for the three month periods ended March 31, 2017, compared to $164,128 during the three months ended March 31, 2016.  Cash flows used by investing activities were $0 for the three month periods ended March 31, 2017 and 2016.
 
During the three months ended March 31, 2017, we issued a total of 48,428,125 shares of our Common Stock. Of these, 42,428,125 shares valued at $128,451 were issued upon conversion of outstanding notes payable, reducing the debt by $48,500 and interest payable by $3,022 and generating a loss on conversion of $76,929. In addition, we issued 6,000,000 shares of our Common Stock valued at $14,400 for $15,000 Canadian ($11,278 US). The $15,000 Canadian was paid directly to a firm which was engaged to conduct a valuation of our patents. We believe that having an independent valuation of our patents will be helpful in connection with our ongoing financing efforts.
 
On March 29, 2016, we issued 10,000,000 shares of our Common Stock having a market value of $100,000 or $0.01 per share, to an unaffiliated company that is assisting us in the development of manufacturing, marketing, sales and distribution contracts for various generic pharmaceuticals and biomedical products in Canada. These services are for a two year period but the value of these shares ($100,000) was expensed in the three month period ended March 31, 2016.
 
In March 2016, our Board of Directors authorized a private offering of our Common Stock in Canada pursuant to Regulation S promulgated under the Securities Act of 1933, as amended, wherein we offered up to 60,000,000 shares of our Common Stock at an offering price of $0.015 Canadian per share for aggregate gross proceeds of up to $900,000 Canadian.   We accepted two subscriptions each of 10,000,000 shares of our Common Stock for $150,000 Canadian, aggregating $300,000 Canadian or approximately $236,550 US.
 
We are not generating revenue from our operations, and our ability to implement our business plan as set forth herein will depend on the future availability of financing. Such financing will be required to enable us to further develop our generic pharmaceuticals business and proprietary drug development program. We intend to raise funds through private placements of our Common Stock and/or debt financing. We estimate that we will require approximately $6 million ($1 million for the generic pharmaceutical operations and $5 million for the proprietary drug development program) to fully implement our business plan in the future and there are no assurances that we will be able to raise this capital. While we are engaged in discussions with various investment banking firms and venture capitalists to provide us these funds, as of the date of this report we have not reached any agreement with any party that has agreed to provide us with the capital necessary to effectuate our business plan. Our inability to obtain sufficient funds from external sources when needed will have a material adverse effect on our plan of operation, results of operations and financial condition.
 
 
17
 
 
Our cost to continue operations as they are now conducted is nominal, but these are expected to increase as we move forward with implementation of our business plan. We do not have sufficient funds to cover the anticipated increase in the relevant expenses. We need to raise additional funds in order to continue our existing operations, to initiate R&D activities, and to finance our plans to expand our operations for the next year. If we are successful in raising additional funds, we expect our operations and business efforts to continue and expand. There are no assurances this will occur.
 
Subsequent Events
 
In April 2017 we engaged in the following transactions:
 
●
We received monies in exchange for a convertible note payable having a face value of $100,000 Canadian (approximately $75,190 US).
 
●
We sold 34,000,000 shares of our Common Stock valued at $98,600 for $85,000 Canadian (approximately $63,912 US).
 
●
We issued 6,666,667 shares of our Common Stock for the purchase of laboratory equipment valued at $22,000.
 
●
We received monies in exchange for a convertible note payable having a face value of $65,000. In connection with this note, 100,000,000 shares of our Common Stock have been reserved for issuance.
 
Inflation
 
Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the three month period ended March 31, 2017.
 
Critical Accounting Estimates
 
The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.
 
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
 
We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.
 
ITEM 4. CONTROLS AND PROCEDURES.
 
Disclosure Controls and Procedures – Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this Report.
 
These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO/CFO to allow timely decisions regarding required disclosure.
 
 
 
18
 
 
Based on this evaluation, our CEO and CFO have concluded that our disclosure controls and procedures were not effective as of March 31, 2017, at reasonable assurance level, for the following reasons:
 
●
Ineffective control environment and lack of qualified full-time CFO who has SEC experience to focus on our financial affairs;
 
●
Lack of qualified and sufficient personnel, and processes to adequately and timely identify making any and all required public disclosures;
 
●
Deficiencies in the period-end reporting process and accounting policies;
 
●
Inadequate internal controls over the application of new accounting principles or the application of existing accounting principles to new transactions;
 
●
Inadequate internal controls relating to the authorization, recognition, capture, and review of transactions, facts, circumstances, and events that could have a material impact on the company’s financial reporting process;
 
●
Deficient revenue recognition policies;
 
●
Inadequate internal controls with respect to inventory transactions; and
 
●
Improper and lack of timely accounting for accruals such as prepaid expenses, accounts payable and accrued liabilities.
 
Our Board of Directors has assigned a priority to the short-term and long-term improvement of our internal control over financial reporting. We are reviewing various potential solutions to remedy the processes that would eliminate the issues that may arise due to the absence of separation of duties within the financial reporting functions. Additionally, the Board of Directors will work with management to continuously review controls and procedures to identified deficiencies and implement remediation within our internal controls over financial reporting and our disclosure controls and procedures.
 
We believe that our financial statements presented in this annual report on Form 10-K fairly present, in all material respects, our financial position, results of operations, and cash flows for all periods presented herein.
 
Inherent Limitations – Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud.  A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.  The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.  Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.  These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple error or mistake. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.
 
Changes in Internal Control over Financial Reporting – There were no changes in our internal control over financial reporting during our fiscal year ended December 31, 2016, which were identified in conjunction with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
PART II. OTHER INFORMATION
 
ITEM 1. LEGAL PROCEEDINGS
 
Other than the matter discussed above under “GMP Manufacturing” we are not party to any material legal proceedings, nor have any such actions been threatened against us.
 
ITEM 1A. RISK FACTORS
 
We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.
 
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
During the three months ended March 31, 2017, we issued a total of 48,428,125 shares of our Common Stock. Of these 42,428,125 shares valued at $128,451 were issued upon conversion of outstanding notes payable, reducing the debt by $48,500 and interest payable by $3,022 and generating a loss on conversion of $76,929.
 
In addition, we issued 6,000,000 shares of our Common Stock valued at $14,400 for $15,000 Canadian ($11,278 US). The $15,000 Canadian was paid directly to a firm which was engaged to conduct a valuation of our patents.

 
19
 
 
Subsequent Events
 
In April 2017 we engaged in the following transactions:
 
●
We received monies in exchange for a convertible note payable having a face value of $100,000 Canadian (approximately $75,190 US).
 
●
We sold 34,000,000 shares of our Common Stock valued at $98,600 for $85,000 Canadian (approximately $63,912 US).
 
●
We issued 6,666,667 shares of our Common Stock for the purchase of laboratory equipment valued at $22,000.
 
●
We received monies in exchange for a convertible note payable having a face value of $65,000.In connection with this note, 100,000,000 shares of our Common Stock have been reserved for issuance.
 
The funds obtained from these transactions were used for working capital, including the development of our new business described above under “Plan of Operation.”
 
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
 
None
 
ITEM 4. MINE SAFETY DISCLOSURE
 
Not Applicable
 
ITEM 5. OTHER INFORMATION
 
None
 
ITEM 6. EXHIBITS
 
Exhibit No.
 
Description
 
 
 
 31.1
 
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
 
 
 31.2
 
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
 
 
 32
 
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
101.INS
 
XBRL Instance Document*
101.SCH
 
XBRL Schema Document*
101.CAL
 
XBRL Calculation Linkbase Document*
101.DEF
 
XBRL Definition Linkbase Document*
101.LAB
 
XBRL Label Linkbase Document*
101.PRE
 
XBRL Presentation Linkbase Document*
 
 
 
______________________
* Pursuant to Rule 406T of Regulation S-T, these interactive data files are not deemed filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act or Section 18 of the Securities Exchange Act and otherwise not subject to liability.
 
 
20
 
 
SIGNATURES
 
Pursuant to the requirements of Section 12 of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on May 12, 2017.
 
 
SUNSHINE BIOPHARMA, INC.
 
 
 
 
 
 
By:
s/ Dr. Steve N. Slilaty
 
 
 
Dr. Steve N. Slilaty,
 
 
 
Principal Executive Officer
 
 
 
 
 
 
 
 
 
 
By:
s/ Camille Sebaaly
 
 
 
Camille Sebaaly,
Principal Financial Officer and
 
 
 
Principal Accounting Officer
 
 
 
 
21
 EX-31.1 2 sbfm_ex311.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 Blueprint
 
Exhibit 31.1
 
 
CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002
 
I, Steve N. Slilaty, certify that:
 
1.            I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.;
 
2.            Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.            Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.            The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a.           Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b.           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c.           Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
 
d.           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.            The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a.           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b.           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
 
Dated: May 12, 2017
/s/ Steve N. Slilaty                                      
Steve N. Slilaty, Chief Executive Officer
 
 
 
 
 EX-31.2 3 sbfm_ex312.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 Blueprint
 
Exhibit 31.2
 
 
CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES OXLEY ACT OF 2002
 
I, Camille Sebaaly, certify that:
 
1.            I have reviewed this quarterly report on Form 10-Q of Sunshine Biopharma, Inc.;
 
2.            Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.            Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.            The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a.           Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b.           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c.           Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
 
d.           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.            The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a.           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b.           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Dated: May 12, 2017
/s/ Camille Sebaaly                                     
Camille Sebaaly, Chief Financial Officer
 
 EX-32 4 sbfm_ex32.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Blueprint
 
Exhibit 32
 
CERTIFICATION PURSUANT TO
18 USC, SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with this quarterly report of Sunshine Biopharma, Inc. (the “Company”) on Form 10-Q for the nine month period ended September 30, 2016, as filed with the Securities and Exchange Commission on May 12, 2017 (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:
 
1. 
The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2. 
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: May 12, 2017
/s/ Steve N. Slilaty                                      
Steve N. Slilaty, Chief Executive Officer
 
 
Dated: May 12, 2017
/s/ Camille Sebaaly                                     
Camille Sebaaly, Chief Financial Officer
GRAPHIC 5 fig1.jpg IMAGE begin 644 fig1.jpg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fig2.jpg IMAGE begin 644 fig2.jpg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end GRAPHIC 7 fig3.jpg IMAGE begin 644 fig3.jpg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end GRAPHIC 8 fig4.jpg IMAGE begin 644 fig4.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 Z17AI9@ 34T *@ @ U$0 $ M ! 0 %$1 0 ! %$2 0 ! #_VP!# @&!@<& M!0@'!P<)"0@*#!0-# L+#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$ @$" M! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 5 M8G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F M9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! M (1 Q$ /P#RFVMX3:0DPQDE!DE1Z5+]F@_YX1_]\BBT_P"/.'_<'\JEKZ*$ M(\JT/#G.7,]2+[-!_P \(_\ OD4?9H/^>$?_ 'R*EHJN2/8GGEW(OLT'_/"/ M_OD4?9H/^>$?_?(J6BCDCV#GEW(OLT'_ #PC_P"^11]F@_YX1_\ ?(J6K-GI MU[J$GEV5G/<.1G;%&6/Z4G&"W!2F]F4?LT'_ #PC_P"^11]F@_YX1_\ ?(K4 MO-$U73E5KW3;NW5NAEA90?S%4*%&#VL-RFMV1?9H/^>$?_?(H^S0?\\(_P#O MD5+4\%I<7)Q#$S>_:IG[."O*R1=*-:K+EIIM^13^S6__ #PC_P"^!1]F@_YX M1_\ ?(KHK3PX[N#=RE$[B,9;]>*Z2U\.>%)(MMPVI128 W[E8$^N *X7F6"4 MN7F1Z\,@S.4>?D:/.OLT'_/"/_OD4?9H/^>$?_?(KN=1^'S^3+<:%J,6I11# M+Q$;)1]!_%^'I7%LI5BK A@<$$8(KMIRI55>%F>77HU\/+EJIID/V:#_ )X1 M_P#?(H^S0?\ /"/_ +Y%2T5IR1[&'/+N1?9H/^>$?_?(H^S0?\\(_P#OD5+1 M1R1[!SR[D7V:#_GA'_WR*/LT'_/"/_OD5+11R1[!SR[D7V:#_GC'_P!\BC[- M!_SPC_[X%2T4P<\NY%]F@_P">$?\ WR*/LT'_ #PC_P"^14M%')'L'/+N M1?9H/^>$?_?(I?LT'_/"/_OD5)7=^#_ACJ?B4)=7+_8K!@2'(S(_IA?3W-14 M=.FKR+@JDW:)Y_\ 9H/^>,?_ 'P*/LT'_/&/_OD5])67P?\ "=JK"6VFNBW0 MS2GCZ8Q4UQ\)?"$T#1II[0LPP'CE;$?_ M 'R*7[-!_P \(_\ OD5ZYXB^"E[;"2XT&Z%S&,G[/-\K_0'H?QQ7E$?\ WR*/LT'_ #PC_P"^ M14H!)Q5R+2KV8*5@8 ]VXIU)T:?QM(NC1Q%=VI)OT,[[-;_\\8_^^12?9H/^ M>,?_ 'R*V7T&^5TN+,?_?(H^S0?\\(_^^14M%=')'L$?_?(H^S0?\\(_P#O MD5+11R1[!SR[D7V:#_GA'_WR*/LT'_/"/_OD5+11R1[!SR[D7V:#_GA'_P!\ MBC[-!_SQC_[X%2T4P<\NY%]F@_P">$?\ WR*/LT'_ #PC_P"^14M%')'L M'/+N1?9H/^>$?_?(H^S0?\\(_P#OD5+11R1[!SR[D7V:#_GA'_WR*/LT'_/" M/_OD5+11R1[!SR[D7V:#_GA'_P!\BC[-!_SPC_[Y%2T4P<\NY%]F@_P"> M$?\ WR*/LT'_ #PC_P"^14M%')'L'/+N1?9H/^>,?_? H^S0?\\(_P#OD5+1 M1R1[!SR[D-K_ ,>D/^X/Y5-4-K_QZ0_[@_E4U%/X$$_C844451 58MK.:[?; M$OU)Z4VW@,\H7^'N:ZFQA2*(*@P*\C,LS6&]R&LOR/ILBR%X]^TJZ0_,N^$O M T&JZ@@O)6,49!=5XW>U?06FZ?::=9QV]G;QPQ*.%10*\1T;59-)O5G5=R'A MUSU'^->M:)XITS4H$5+E4DQ]R0X(KR:..E7C:I+4]/-,H^J5.:C#W/ZW-V2) M)D*2(KHPP589!KQCXJ?#RVL;1]?TB$QHK#[3 @^4 _Q@=O>O:0Z$9##'UKF/ M&FJ0PZ.]DICD>[_=.A(.$(^;(^G'XUV4:TJ
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ⅅ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end EX-101.INS 9 sbfm-20170331.xml XBRL INSTANCE DOCUMENT 0001402328 2017-01-01 2017-03-31 0001402328 2017-03-31 0001402328 2016-12-31 0001402328 2016-01-01 2016-03-31 0001402328 2015-12-31 0001402328 2016-03-31 0001402328 us-gaap:SeriesAPreferredStockMember 2016-12-31 0001402328 us-gaap:SeriesAPreferredStockMember 2017-03-31 0001402328 us-gaap:SeriesBPreferredStockMember 2016-12-31 0001402328 us-gaap:SeriesBPreferredStockMember 2017-03-31 0001402328 2017-05-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares Sunshine Biopharma, Inc 0001402328 10-Q 2017-03-31 false --12-31 No No Yes Smaller Reporting Company Q1 2017 0.001 0.001 3000000000 3000000000 0.10 0.10 0.10 0.10 850000 850000 500000 500000 5420 5944 17989 58460 846 1007 17143 57453 23409 64404 0 0 284452 274104 284452 274104 1171 9011 27953 28122 183889 167032 71439 69939 0 0 50000 50000 23409 64404 -261043 -209700 -12773657 -12577954 1903 394 11642783 11548460 817928 769400 2797 2272 58918 0 817927983 769399858 817927983 769399858 0 0 500000 500000 0 0 500000 500000 0 0 25937 14184 518 15244 15600 6800 14904 28099 42965 0 7401 3269 1665 2086 -108990 -69682 108990 69682 9144 6954 -639 0 0 25000 76929 253658 -195702 -305294 -86712 -235612 805604089 215596040 0 0 -194193 -315285 1509 -9991 3022 3120 -639 0 -14400 0 76929 253658 -108037 -81598 -7840 3834 -171 -52116 -161 44 0 0 0 0 66218 164128 0 79128 2000 3000 13962 0 50256 82000 1509 -9991 -41819 82530 17143 57453 50798 123337 128451 377814 14400 100000 0 0 0 0 <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Mountain West Business Solutions, Inc. (&#8220;MWBS&#8221;) was incorporated on August 31, 2006 in the State of Colorado. Sunshine Etopo, Inc. (formerly Sunshine Biopharma, Inc.) was incorporated in the State of Colorado on August 17, 2009. Effective October 15, 2009, MWBS was acquired by Sunshine Etopo, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its name to Sunshine Biopharma, Inc. Sunshine Etopo, Inc. has been inactive and was recently dissolved. In July 2014, the Company formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. The financial statements represent the consolidated activity of Sunshine Biopharma, Inc. and Sunshine Biopharma Canada Inc. (hereinafter together referred to as the &#34;Company&#34;). The Company was formed for the purposes of conducting research, development and commercialization of drugs for the treatment of various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board of Directors of the Company.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The Company&#8217;s wholly owned Canadian Subsidiary, Sunshine Biopharma Canada Inc. (&#8220;Sunshine Canada&#8221;) was formed for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. Sunshine Canada has recently signed licensing agreements for four (4) generic prescription drugs for treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia). In addition, Sunshine Canada is currently evaluating several other generic products for in-licensing and is working on securing a Drug Establishment License (&#8220;DEL&#8221;) and a Drug Identification Number (&#8220;DIN&#8221;) per product from Health Canada. Once the DEL and the DIN&#8217;s are secured, Sunshine Canada will begin its generic pharmaceuticals marketing and sales program in Canada and overseas.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In addition, the Company has been and continues to work on the development of its proprietary anticancer drug, Adva-27a. The next series of steps in the development of Adva-27a include (i) GMP-manufacturing of a 2-kilogram quantity of the drug, (ii) completing requisite IND-enabling studies, and (iii) conducting Phase I clinical trials. In the preclinical studies, Adva-27a was shown to be effective at destroying multidrug resistant cancer cells including Pancreatic Cancer, Breast Cancer, Lung Cancer and Uterine Sarcoma, cells.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During the last three month period the Company has continued to raise money through stock sales and borrowings.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="margin: 0; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">The Company&#8217;s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company&#8217;s generics business and proprietary drug development program.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">See the Notes in the 2016 Form 10-K consolidated financial statements for a complete summary of the Company&#8217;s significant accounting policies. This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>PRINCIPLES OF CONSOLIDATION</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>USE OF ESTIMATES</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>CASH AND CASH EQUIVALENTS</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">For the Balance Sheets and Statement of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $17,143 and $57,453 as of March 31, 2017 and December 31, 2016, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>EARNINGS PER SHARE</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The Company has adopted the FASB ASC Topic 260 regarding earnings / loss per share, which provides for calculation of &#8220;basic&#8221; and &#8220;diluted&#8221; earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Other than the Notes Payable specified under Note 4 and Note 5 below, there were no potentially dilutive instruments outstanding during the interim period ended March 31, 2017 or the year ended December 31, 2016.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>INCOME TAXES</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company follows the asset and liability method of accounting for deferred income taxes. The asset and liability method requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between financial accounting and tax bases of assets and liabilities. The Company accounts for income taxes pursuant to ASC 740. There was no increase in liabilities for unrecognized tax benefits as a result of this implementation. The Company recognizes accrued interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expense.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>FUNCTIONAL CURRENCY</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar. The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Income statement accounts are translated using the weighted average exchange rate for the period.</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders&#8217; equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif"><i>REVENUE RECOGNITION</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Since inception, the Company has been focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Following its recent entry into the generic pharmaceuticals business, the Company has become a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications. The Company intends to recognize revenues from the sales of generic pharmaceuticals, if or when they occur, at the time the products are sold and collectability is assured. In the event the Company provides consulting services in the future, revenues from such services will be recognized when the services are rendered and invoiced.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>GOING CONCERN</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Since inception, the Company has had recurring operating losses and negative operating cash flows. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company&#8217;s continuation as a going concern is dependent on its ability to obtain additional financing to fund operations, implement its business model, and ultimately, attain profitable operations. The Company will need to secure additional funds through various means, including equity and debt financing or any similar financing. There can be no assurance that the Company will be able to obtain additional equity or debt financing, if and when needed, on terms acceptable to the Company, or at all. Any additional equity or debt financing may involve substantial dilution to the Company&#8217;s stockholders, restrictive covenants or high interest costs. The Company&#8217;s long-term liquidity also depends upon its ability to generate revenues and achieve profitability.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The unaudited financial information included for the three month interim period ended March 31, 2017 was taken from the books and records of the Company without audit. However, such information reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to reflect properly the results of the interim periods presented. The results of operations for the three month interim period ended March 31, 2017 are not necessarily indicative of the results expected for the fiscal year ending December 31, 2017.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">A Note Payable having a face value of $21,439 and a maturity date of December 31, 2017 was entered into on December 31, 2016. This Note accrues interest at a rate of 12% per annum and is convertible after December 31, 2016 into $0.001 par value Common Stock at a price 35% below market value. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">A Note payable dated July 1, 2016, having a face value of $55,000 and a principal balance of $48,500 at December 31, 2016, accrued interest at 10%. This note was convertible into $0.001 par value Common Stock at a price 40% below market value. During the three month period ended March 31, 2017, a total of $48,500 in principal and $3,022 of interest was converted into $0.001 par value Common Stock leaving a principal balance of $-0-. In connection with this conversion, 42,528,125 shares of $0.001 par value Common Stock valued at $128,451 were issued generating a loss of $76,929 on conversion.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On February 10, 2017, the Company received net proceeds of $48,000 in exchange for a note payable having a face value of $50,000 and accruing interest at the rate of 8% per annum. The note, due on November 20, 2017, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 39% below market value. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. In connection with this note, 204,918,033 shares of the Company&#8217;s Common Stock have been reserved for issuance.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">At March 31, 2017 and December 31, 2016, accrued interest on Notes Payable was $15,124 and $9,011, respectively.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In December 2016, the Company received monies from its CEO in exchange for a note payable having a principal amount of $90,000 Canadian ($67,032 US) &#8217;&#8211;with interest at 12% due March 31, 2017. The note is convertible any time after the date of issuance into $0.001 par value Common Stock at a price 35% below market value. The Company estimated that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. This note is collateralized by all of the assets of the Company. In the event of default, the interest rate will increased to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note, together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US) paid to the Company on March 28, 2017, was renewed for a 90-day period under the same terms and conditions as the original note. The new note now having a face value of $96,021 Canadian ($72,198 US) is due on June 30, 2017.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">A note payable held by a private individual who became a principal shareholder of the Company having a face value of $100,000 at December 31, 2016 and a maturity date of March 31, 2017, accrues interest at 12%. The Note is convertible any time from the date of issuance into $0.001 par value Common Stock at a 35% discount from market price. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. On March 31, 2017, the note&#8217;s principal balance of $100,000 plus accrued interest of $11,715 was renewed for a period of 90-day under the same terms and conditions as the original note. The new note now having a face value of $111,715 matures on June 30, 2017.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During the three months ended March 31, 2017, the Company issued a total of 48,428,125 shares of $0.001 par value Common Stock. Of these 42,428,125 shares valued at $128,451 were issued upon conversion of outstanding notes payable, reducing the debt by $48,500 and interest payable by $3,022 and generating a loss on conversion of $76,929.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In addition, the Company issued 6,000,000 shares of $0.001 par value Common Stock valued at $14,400 for $15,000 Canadian ($11,278 US). The $15,000 Canadian was paid directly to a firm which was engaged to conduct a valuation of the Company&#8217;s patents. The difference of $3,122 was recorded as a consulting expense.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In connection with its convertible notes payable, the Company has 204,918,033 shares of its common stock reserved for issuance at March 31, 2017.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The Company declared no dividends through March 31, 2017.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Earnings (loss) per share is computed using the weighted average number of Common Shares outstanding during the period. The Company has adopted ASC 260 (formerly SFAS128), &#8220;Earnings per Share&#8221;.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">In 2016, the Company entered into License Agreements for the following four Generic Drugs:</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Anastrozole (brand name Arimidex&#174; by AstraZenica) for treatment of Breast Cancer</font></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: top; font: 8pt Times New Roman, Times, Serif; padding: 0.75pt"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="padding: 0.75pt; font: 8pt Times New Roman, Times, Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Letrozole (brand name Femara&#174; by Novartis) for treatment of Breast Cancer</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <table cellpadding="0" style="width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: top; width: 48px; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="padding: 0.75pt; text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Bicalutamide (brand name Casodex&#174; by AstraZenica) for treatment of Prostate Cancer</font></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="vertical-align: top; padding: 0.75pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="padding: 0.75pt; text-align: justify; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Finasteride (brand name Propecia&#174; by Merck) for treatment of Benign Prostatic Hyperplasia</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">The cost of these Licenses has been fully expensed.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">For a complete set of footnotes, reference is made to the Company&#8217;s Report on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission and the audited financial statements and notes included therein.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. Loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">A deferred tax asset at each date has been offset by a 100% valuation allowance.</font></p> <p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">As part of a subscription agreement entered into in 2016, the Company has an obligation to pay a royalty of 5% of net sales on one of its generic products (Anastrozole) for a period of three (3) years from the date of the first sale of that product.</font></p> <p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p> <p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In addition to the related party transactions detailed in Note 5 above, during the three month period ended March 31, 2017, the Company paid its Officers and Directors cash compensation totaling $42,965. $1,519 was paid to the Company&#8217;s COO and $41,446 was paid to the Company&#8217;s CEO.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">During the fiscal year ended December 31, 2016, Advanomics Corporation paid on behalf of the Company $13,725 Canadian in patenting fees. Advanomics was fully reimbursed by the Company in January 2017.&#160;</font></p> <p style="margin: 0pt; font: 8pt Times New Roman, Times, Serif"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In April 2017, the Company received monies in exchange for a convertible note payable having a face value of $100,000 Canadian (approximately $75,190 US).</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">On April 3, 2017, the Company sold 34,000,000 shares of its $0.001 par value Common Stock valued at $98,600 for $85,000 Canadian (approximately $63,912 US).</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On April 24, 2017, the Company issued 6,666,667 shares of its $0.001 par value Common Stock for the purchase of laboratory equipment valued at $22,000.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">On April 26, 2017, the Company received monies in exchange for a convertible note payable having a face value of $65,000. In connection with this note, 100,000,000 shares of the Company&#8217;s Common Stock have been reserved for issuance.</font></p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the Balance Sheets and Statement of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $17,143 and $57,453 as of March 31, 2017 and December 31, 2016, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000.</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has adopted the FASB ASC Topic 260 regarding earnings / loss per share, which provides for calculation of &#8220;basic&#8221; and &#8220;diluted&#8221; earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">Other than the Notes Payable specified under Note 4 and Note 5 below, there were no potentially dilutive instruments outstanding during the interim period ended March 31, 2017 or the year ended December 31, 2016.</p> <p style="margin: 0; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">The Company follows the asset and liability method of accounting for deferred income taxes. The asset and liability method requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between financial accounting and tax bases of assets and liabilities. The Company accounts for income taxes pursuant to ASC 740. There was no increase in liabilities for unrecognized tax benefits as a result of this implementation. The Company recognizes</font></p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar. The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 48px; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.</font></td></tr> </table> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 48px; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#9679;</font></td> <td style="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">Income statement accounts are translated using the weighted average exchange rate for the period.</font></td></tr> </table> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders&#8217; equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">Since inception, the Company has been focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Following its recent entry into the generic pharmaceuticals business, the Company has become a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications. The Company intends to recognize revenues from the sales of generic pharmaceuticals, if or when they occur, at the time the products are sold and collectability is assured. In the event the Company provides consulting services in the future, revenues from such services will be recognized when the services are rendered and invoiced.</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Since inception, the Company has had recurring operating losses and negative operating cash flows. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern.</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The Company&#8217;s continuation as a going concern is dependent on its ability to obtain additional financing to fund operations, implement its business model, and ultimately, attain profitable operations. The Company will need to secure additional funds through various means, including equity and debt financing or any similar financing. There can be no assurance that the Company will be able to obtain additional equity or debt financing, if and when needed, on terms acceptable to the Company, or at all. Any additional equity or debt financing may involve substantial dilution to the Company&#8217;s stockholders, restrictive covenants or high interest costs. The Company&#8217;s long-term liquidity also depends upon its ability to generate revenues and achieve profitability.</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"></p> 48428125 525 15244 858594650 204918033 EX-101.SCH 10 sbfm-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Unaudited Statement Of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Unaudited Statement Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - 1. Descriptions of Business link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 2. Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 3. Unaudited Financial Information link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 4. Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 5. Notes Payable Related Party link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 6. Issuance of Common Stock link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 7. Earnings (Loss) per Share link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 8. Generic Drugs License link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 9. Financial Statements link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 10. Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 11. Royalties Payable link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 12. Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 13. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 4. Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 6. Issuance of Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 11. Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 sbfm-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 12 sbfm-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 13 sbfm-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Series A Preferred Stock Series B Preferred Stock Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets: Cash and cash equivalents Prepaid expenses Total Current Assets Equipment (net of $2,797 and $2,272 depreciation, resepctively) Patents (net of $58,918 amortization and $556,120 impairment) TOTAL ASSETS LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Current portion of notes payable Current portion of notes payable - related party Accounts payable Interest payable Total current liabilities TOTAL LIABILITIES Commitments and Contingencies SHAREHOLDERS' (Deficit) Preferred stock, Series A $0.10 par value per share; Authorized 850,000 Shares; Issued and outstanding -0- shares. Preferred stock, Series B $0.10 par value per share; Authorized 500,000 Shares; Issued and outstanding 500,000 shares. Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 817,927,983 and 769,399,858 at March 31, 2017 and December 31, 2016, respectively. Reserved for issuance 204,918,033 at March 31, 2017 Capital paid in excess of par value Accumulated comprehensive income Accumulated (Deficit) TOTAL SHAREHOLDERS' EQUITY (DEFICIT) TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Statement [Table] Statement [Line Items] Depreciation, equipment Amortization, patent SHAREHOLDERS' EQUITY Preferred stock, par value Preferred stock shares authorized Preferred stock shares issued Preferred stock shares outstanding Common stock, par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Common stock shares reserved for issuance Income Statement [Abstract] Revenue: General & Administrative Expenses Accounting Amortization & depreciation Consulting Legal Licenses Office Officer & director renumeration Stock Transfer Fee Travel Total G & A (Loss) from operations Other Income (expense) Foreign exchange gain Interest expense Gain from interest forgiveness Litigation settlement proceeds Debt release Loss on debt conversions Total Other (Expense) Net (Loss) Basic (Loss) per common share Weighted Average Common Shares Oustanding Net Income (Loss) Other comprehensive income: Unrealized Gain (Loss) from Foreign Exchange Translations Comprehensive (Loss) Weighted Average Common Shares Outstanding Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net Gain (Loss) Adjustments to reconcile net loss to net cash used in operating activities: Foreign exchange loss Depreciation and amortization Stock issued for payment interest Debt forgiveness Loss on debt conversion Stock issued for payment of expenses (Increase) decrease in prepaid expenses Increase (decrease) in Accounts Payable & accrued expenses Increase (decrease) in interest payable Net Cash Flows (used) in operations Cash Flows From Investing Activities: Purchase of equipment Net Cash Flows (used) in Investing activities Cash Flows From Financing Activities: Proceed from note payable Note payable used to pay expenses Note payable used to pay origionation fees & interest Sale of common stock Net Cash Flows provided by financing activities Net Increase (Decrease) In Cash and cash equivalents Foreign currency translation adjustment Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplementary Disclosure Of Cash Flow Information: Stock issued for services, licenses and other assets Stock issued for note conversions including interest Stock issued for interest Stock issued for payment of expenses Loan proceeds used to pay expenses Cash paid for interest Cash paid for income taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] 1. Descriptions of Business Accounting Policies [Abstract] 2. Summary of Significant Accounting Policies 3. Unaudited Financial Information Notes to Financial Statements 4. Notes Payable Notes Payable Related Party 5. Notes Payable Related Party Text Block [Abstract] 6. Issuance of Common Stock Earnings Loss Per Share 7. Earnings (Loss) per Share Generic Drugs License 8. Generic Drugs License Financial Statements 9. Financial Statements Income Tax Disclosure [Abstract] 10. Income Taxes 11. Royalties Payable Related Party Transactions [Abstract] 12. Related Party Transactions 13. Subsequent Events PRINCIPLES OF CONSOLIDATION USE OF ESTIMATES CASH AND CASH EQUIVALENTS EARNINGS PER SHARE INCOME TAXES FOREIGN CURRENCY REVENUE RECOGNITION AMORTIZATION AND DEPRECIATION GOING CONCERN Summary Of Significant Accounting Policies Details Narrative Interest accrued Issuance of Common Stock Shares issued Par value of common stock Income Taxes Details Narrative Net operating loss carryforwards Deferred tax asset, operating loss carryforwards Valuation allowance Change in the valuation allowance Custom Element. Custom Element. Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity General and Administrative Expense Operating Income (Loss) Interest Expense Induced Conversion of Convertible Debt Expense Nonoperating Income (Expense) Foreign Currency Transaction Gain (Loss), before Tax StockIssuedForPaymentOfExpenses Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments to Acquire Productive Assets Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash EX-101.PRE 14 sbfm-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 15 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2017
May 12, 2017
Document And Entity Information    
Entity Registrant Name Sunshine Biopharma, Inc  
Entity Central Index Key 0001402328  
Document Type 10-Q  
Document Period End Date Mar. 31, 2017  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   858,594,650
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2017  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet (Unaudited) - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Current Assets:    
Cash and cash equivalents $ 17,143 $ 57,453
Prepaid expenses 846 1,007
Total Current Assets 17,989 58,460
Equipment (net of $2,797 and $2,272 depreciation, resepctively) 5,420 5,944
Patents (net of $58,918 amortization and $556,120 impairment) 0 0
TOTAL ASSETS 23,409 64,404
Current Liabilities:    
Current portion of notes payable 71,439 69,939
Current portion of notes payable - related party 183,889 167,032
Accounts payable 27,953 28,122
Interest payable 1,171 9,011
Total current liabilities 284,452 274,104
TOTAL LIABILITIES 284,452 274,104
Commitments and Contingencies
SHAREHOLDERS' (Deficit)    
Preferred stock, Series A $0.10 par value per share; Authorized 850,000 Shares; Issued and outstanding -0- shares. 0 0
Preferred stock, Series B $0.10 par value per share; Authorized 500,000 Shares; Issued and outstanding 500,000 shares. 50,000 50,000
Common Stock, $0.001 par value per share; Authorized 3,000,000,000 Shares; Issued and outstanding 817,927,983 and 769,399,858 at March 31, 2017 and December 31, 2016, respectively. Reserved for issuance 204,918,033 at March 31, 2017 817,928 769,400
Capital paid in excess of par value 11,642,783 11,548,460
Accumulated comprehensive income 1,903 394
Accumulated (Deficit) (12,773,657) (12,577,954)
TOTAL SHAREHOLDERS' EQUITY (DEFICIT) (261,043) (209,700)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) $ 23,409 $ 64,404
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet (Parenthetical) - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Depreciation, equipment $ 2,797 $ 2,272
Amortization, patent $ 58,918 $ 0
SHAREHOLDERS' EQUITY    
Common stock, par value $ 0.001 $ 0.001
Common stock shares authorized 3,000,000,000 3,000,000,000
Common stock shares issued 817,927,983 769,399,858
Common stock shares outstanding 817,927,983 769,399,858
Common stock shares reserved for issuance 204,918,033  
Series A Preferred Stock    
SHAREHOLDERS' EQUITY    
Preferred stock, par value $ 0.10 $ 0.10
Preferred stock shares authorized 850,000 850,000
Preferred stock shares issued 0 0
Preferred stock shares outstanding 0 0
Series B Preferred Stock    
SHAREHOLDERS' EQUITY    
Preferred stock, par value $ 0.10 $ 0.10
Preferred stock shares authorized 500,000 500,000
Preferred stock shares issued 500,000 500,000
Preferred stock shares outstanding 500,000 500,000
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Unaudited Statement Of Operations and Comprehensive Loss - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Income Statement [Abstract]    
Revenue: $ 0 $ 0
General & Administrative Expenses    
Accounting 15,600 6,800
Amortization & depreciation 518 15,244
Consulting 25,937 14,184
Legal 14,904 28,099
Office 7,401 3,269
Officer & director renumeration 42,965 0
Stock Transfer Fee 1,665 2,086
Total G & A 108,990 69,682
(Loss) from operations (108,990) (69,682)
Other Income (expense)    
Foreign exchange gain (639) 0
Interest expense (9,144) (6,954)
Litigation settlement proceeds 0 25,000
Loss on debt conversions (76,929) (253,658)
Total Other (Expense) (86,712) (235,612)
Net (Loss) $ (195,702) $ (305,294)
Basic (Loss) per common share $ 0 $ 0
Weighted Average Common Shares Oustanding 805,604,089 215,596,040
Net Income (Loss) $ (195,702) $ (305,294)
Other comprehensive income:    
Unrealized Gain (Loss) from Foreign Exchange Translations 1,509 (9,991)
Comprehensive (Loss) $ (194,193) $ (315,285)
Basic (Loss) per common share $ 0 $ 0
Weighted Average Common Shares Outstanding 805,604,089 215,596,040
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Unaudited Statement Of Cash Flows - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Cash Flows From Operating Activities:    
Net Gain (Loss) $ (195,702) $ (305,294)
Adjustments to reconcile net loss to net cash used in operating activities:    
Foreign exchange loss 639 0
Depreciation and amortization 525 15,244
Stock issued for payment interest 3,022 3,120
Loss on debt conversion 76,929 253,658
Stock issued for payment of expenses 14,400 0
(Increase) decrease in prepaid expenses 161 (44)
Increase (decrease) in Accounts Payable & accrued expenses (171) (52,116)
Increase (decrease) in interest payable (7,840) 3,834
Net Cash Flows (used) in operations (108,037) (81,598)
Cash Flows From Investing Activities:    
Purchase of equipment 0 0
Net Cash Flows (used) in Investing activities 0 0
Cash Flows From Financing Activities:    
Proceed from note payable 50,256 82,000
Note payable used to pay expenses 13,962 0
Note payable used to pay origionation fees & interest 2,000 3,000
Sale of common stock 0 79,128
Net Cash Flows provided by financing activities 66,218 164,128
Net Increase (Decrease) In Cash and cash equivalents (41,819) 82,530
Foreign currency translation adjustment 1,509 (9,991)
Cash and cash equivalents at beginning of period 57,453 50,798
Cash and cash equivalents at end of period 17,143 123,337
Supplementary Disclosure Of Cash Flow Information:    
Stock issued for services, licenses and other assets 14,400 100,000
Stock issued for note conversions including interest 128,451 377,814
Cash paid for interest 0 0
Cash paid for income taxes $ 0 $ 0
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
1. Descriptions of Business
 3 Months Ended
Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
1. Descriptions of Business

Mountain West Business Solutions, Inc. (“MWBS”) was incorporated on August 31, 2006 in the State of Colorado. Sunshine Etopo, Inc. (formerly Sunshine Biopharma, Inc.) was incorporated in the State of Colorado on August 17, 2009. Effective October 15, 2009, MWBS was acquired by Sunshine Etopo, Inc. in a transaction classified as a reverse acquisition. MWBS concurrently changed its name to Sunshine Biopharma, Inc. Sunshine Etopo, Inc. has been inactive and was recently dissolved. In July 2014, the Company formed a wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc. The financial statements represent the consolidated activity of Sunshine Biopharma, Inc. and Sunshine Biopharma Canada Inc. (hereinafter together referred to as the "Company"). The Company was formed for the purposes of conducting research, development and commercialization of drugs for the treatment of various forms of cancer. The Company may also engage in any other business that is permitted by law, as designated by the Board of Directors of the Company.

 

The Company’s wholly owned Canadian Subsidiary, Sunshine Biopharma Canada Inc. (“Sunshine Canada”) was formed for the purposes of offering generic pharmaceutical products in Canada and elsewhere around the world. Sunshine Canada has recently signed licensing agreements for four (4) generic prescription drugs for treatment of breast cancer, prostate cancer and BPH (Benign Prostatic Hyperplasia). In addition, Sunshine Canada is currently evaluating several other generic products for in-licensing and is working on securing a Drug Establishment License (“DEL”) and a Drug Identification Number (“DIN”) per product from Health Canada. Once the DEL and the DIN’s are secured, Sunshine Canada will begin its generic pharmaceuticals marketing and sales program in Canada and overseas.

 

In addition, the Company has been and continues to work on the development of its proprietary anticancer drug, Adva-27a. The next series of steps in the development of Adva-27a include (i) GMP-manufacturing of a 2-kilogram quantity of the drug, (ii) completing requisite IND-enabling studies, and (iii) conducting Phase I clinical trials. In the preclinical studies, Adva-27a was shown to be effective at destroying multidrug resistant cancer cells including Pancreatic Cancer, Breast Cancer, Lung Cancer and Uterine Sarcoma, cells.

 

During the last three month period the Company has continued to raise money through stock sales and borrowings.

 

The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalize the Company’s generics business and proprietary drug development program.
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
2. Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2017
Accounting Policies [Abstract]  
2. Summary of Significant Accounting Policies

See the Notes in the 2016 Form 10-K consolidated financial statements for a complete summary of the Company’s significant accounting policies. This summary of significant accounting policies is presented to assist the reader in understanding the Company's financial statements. The consolidated financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to generally accepted accounting principles and have been consistently applied in the preparation of the financial statements.

  

PRINCIPLES OF CONSOLIDATION

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

 

USE OF ESTIMATES

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

 

CASH AND CASH EQUIVALENTS

 

For the Balance Sheets and Statement of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $17,143 and $57,453 as of March 31, 2017 and December 31, 2016, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000.

 

EARNINGS PER SHARE

 

The Company has adopted the FASB ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.

 

Other than the Notes Payable specified under Note 4 and Note 5 below, there were no potentially dilutive instruments outstanding during the interim period ended March 31, 2017 or the year ended December 31, 2016.

 

INCOME TAXES

 

The Company follows the asset and liability method of accounting for deferred income taxes. The asset and liability method requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between financial accounting and tax bases of assets and liabilities. The Company accounts for income taxes pursuant to ASC 740. There was no increase in liabilities for unrecognized tax benefits as a result of this implementation. The Company recognizes accrued interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expense.

  

FUNCTIONAL CURRENCY

 

The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar. The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:

 

● Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.

 

● Income statement accounts are translated using the weighted average exchange rate for the period.

 

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.

 

REVENUE RECOGNITION

 

Since inception, the Company has been focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Following its recent entry into the generic pharmaceuticals business, the Company has become a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications. The Company intends to recognize revenues from the sales of generic pharmaceuticals, if or when they occur, at the time the products are sold and collectability is assured. In the event the Company provides consulting services in the future, revenues from such services will be recognized when the services are rendered and invoiced.

 

GOING CONCERN

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Since inception, the Company has had recurring operating losses and negative operating cash flows. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company’s continuation as a going concern is dependent on its ability to obtain additional financing to fund operations, implement its business model, and ultimately, attain profitable operations. The Company will need to secure additional funds through various means, including equity and debt financing or any similar financing. There can be no assurance that the Company will be able to obtain additional equity or debt financing, if and when needed, on terms acceptable to the Company, or at all. Any additional equity or debt financing may involve substantial dilution to the Company’s stockholders, restrictive covenants or high interest costs. The Company’s long-term liquidity also depends upon its ability to generate revenues and achieve profitability.

 

The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

 
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
3. Unaudited Financial Information
 3 Months Ended
Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
3. Unaudited Financial Information

The unaudited financial information included for the three month interim period ended March 31, 2017 was taken from the books and records of the Company without audit. However, such information reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management are necessary to reflect properly the results of the interim periods presented. The results of operations for the three month interim period ended March 31, 2017 are not necessarily indicative of the results expected for the fiscal year ending December 31, 2017.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
4. Notes Payable
 3 Months Ended
Mar. 31, 2017
Notes to Financial Statements  
4. Notes Payable

A Note Payable having a face value of $21,439 and a maturity date of December 31, 2017 was entered into on December 31, 2016. This Note accrues interest at a rate of 12% per annum and is convertible after December 31, 2016 into $0.001 par value Common Stock at a price 35% below market value. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature.

 

A Note payable dated July 1, 2016, having a face value of $55,000 and a principal balance of $48,500 at December 31, 2016, accrued interest at 10%. This note was convertible into $0.001 par value Common Stock at a price 40% below market value. During the three month period ended March 31, 2017, a total of $48,500 in principal and $3,022 of interest was converted into $0.001 par value Common Stock leaving a principal balance of $-0-. In connection with this conversion, 42,528,125 shares of $0.001 par value Common Stock valued at $128,451 were issued generating a loss of $76,929 on conversion.

 

On February 10, 2017, the Company received net proceeds of $48,000 in exchange for a note payable having a face value of $50,000 and accruing interest at the rate of 8% per annum. The note, due on November 20, 2017, is convertible after 180 days from issuance into $0.001 par value Common Stock at a price 39% below market value. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. In connection with this note, 204,918,033 shares of the Company’s Common Stock have been reserved for issuance.

  

At March 31, 2017 and December 31, 2016, accrued interest on Notes Payable was $15,124 and $9,011, respectively.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
5. Notes Payable Related Party
 3 Months Ended
Mar. 31, 2017
Notes Payable Related Party  
5. Notes Payable Related Party

In December 2016, the Company received monies from its CEO in exchange for a note payable having a principal amount of $90,000 Canadian ($67,032 US) ’–with interest at 12% due March 31, 2017. The note is convertible any time after the date of issuance into $0.001 par value Common Stock at a price 35% below market value. The Company estimated that the fair value of the convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. Any gain or loss will be recognized at conversion. This note is collateralized by all of the assets of the Company. In the event of default, the interest rate will increased to 18% per annum and a penalty of $1,000 Canadian ($752 US) per day will accrue. On March 31, 2017, the note, together with accrued interest of $3,021 Canadian ($2,271 US) and an additional principal amount of $3,000 Canadian ($2,247 US) paid to the Company on March 28, 2017, was renewed for a 90-day period under the same terms and conditions as the original note. The new note now having a face value of $96,021 Canadian ($72,198 US) is due on June 30, 2017.

 

A note payable held by a private individual who became a principal shareholder of the Company having a face value of $100,000 at December 31, 2016 and a maturity date of March 31, 2017, accrues interest at 12%. The Note is convertible any time from the date of issuance into $0.001 par value Common Stock at a 35% discount from market price. The Company estimates that the fair value of this convertible debt approximates the face value, so no value has been assigned to the beneficial conversion feature. On March 31, 2017, the note’s principal balance of $100,000 plus accrued interest of $11,715 was renewed for a period of 90-day under the same terms and conditions as the original note. The new note now having a face value of $111,715 matures on June 30, 2017.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
6. Issuance of Common Stock
 3 Months Ended
Mar. 31, 2017
Text Block [Abstract]  
6. Issuance of Common Stock

During the three months ended March 31, 2017, the Company issued a total of 48,428,125 shares of $0.001 par value Common Stock. Of these 42,428,125 shares valued at $128,451 were issued upon conversion of outstanding notes payable, reducing the debt by $48,500 and interest payable by $3,022 and generating a loss on conversion of $76,929.

 

In addition, the Company issued 6,000,000 shares of $0.001 par value Common Stock valued at $14,400 for $15,000 Canadian ($11,278 US). The $15,000 Canadian was paid directly to a firm which was engaged to conduct a valuation of the Company’s patents. The difference of $3,122 was recorded as a consulting expense.

 

In connection with its convertible notes payable, the Company has 204,918,033 shares of its common stock reserved for issuance at March 31, 2017.

 

The Company declared no dividends through March 31, 2017.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
7. Earnings (Loss) per Share
 3 Months Ended
Mar. 31, 2017
Earnings Loss Per Share  
7. Earnings (Loss) per Share

Earnings (loss) per share is computed using the weighted average number of Common Shares outstanding during the period. The Company has adopted ASC 260 (formerly SFAS128), “Earnings per Share”.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
8. Generic Drugs License
 3 Months Ended
Mar. 31, 2017
Generic Drugs License  
8. Generic Drugs License

In 2016, the Company entered into License Agreements for the following four Generic Drugs:

 

● Anastrozole (brand name Arimidex® by AstraZenica) for treatment of Breast Cancer
● Letrozole (brand name Femara® by Novartis) for treatment of Breast Cancer

 

● Bicalutamide (brand name Casodex® by AstraZenica) for treatment of Prostate Cancer
● Finasteride (brand name Propecia® by Merck) for treatment of Benign Prostatic Hyperplasia

 

The cost of these Licenses has been fully expensed.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
9. Financial Statements
 3 Months Ended
Mar. 31, 2017
Financial Statements  
9. Financial Statements

For a complete set of footnotes, reference is made to the Company’s Report on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission and the audited financial statements and notes included therein.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
10. Income Taxes
 3 Months Ended
Mar. 31, 2017
Income Tax Disclosure [Abstract]  
10. Income Taxes

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. Loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

 

A deferred tax asset at each date has been offset by a 100% valuation allowance.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
11. Royalties Payable
 3 Months Ended
Mar. 31, 2017
Notes to Financial Statements  
11. Royalties Payable

As part of a subscription agreement entered into in 2016, the Company has an obligation to pay a royalty of 5% of net sales on one of its generic products (Anastrozole) for a period of three (3) years from the date of the first sale of that product.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
12. Related Party Transactions
 3 Months Ended
Mar. 31, 2017
Related Party Transactions [Abstract]  
12. Related Party Transactions

In addition to the related party transactions detailed in Note 5 above, during the three month period ended March 31, 2017, the Company paid its Officers and Directors cash compensation totaling $42,965. $1,519 was paid to the Company’s COO and $41,446 was paid to the Company’s CEO.

 

During the fiscal year ended December 31, 2016, Advanomics Corporation paid on behalf of the Company $13,725 Canadian in patenting fees. Advanomics was fully reimbursed by the Company in January 2017. 
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
13. Subsequent Events
 3 Months Ended
Mar. 31, 2017
Notes to Financial Statements  
13. Subsequent Events

In April 2017, the Company received monies in exchange for a convertible note payable having a face value of $100,000 Canadian (approximately $75,190 US).

 

On April 3, 2017, the Company sold 34,000,000 shares of its $0.001 par value Common Stock valued at $98,600 for $85,000 Canadian (approximately $63,912 US).

 

On April 24, 2017, the Company issued 6,666,667 shares of its $0.001 par value Common Stock for the purchase of laboratory equipment valued at $22,000.

 

On April 26, 2017, the Company received monies in exchange for a convertible note payable having a face value of $65,000. In connection with this note, 100,000,000 shares of the Company’s Common Stock have been reserved for issuance.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
2. Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2017
Accounting Policies [Abstract]  
PRINCIPLES OF CONSOLIDATION

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
USE OF ESTIMATES

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant estimates and assumptions made by management are valuation of equity instruments, depreciation of property and equipment, and deferred tax asset valuation. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.
CASH AND CASH EQUIVALENTS

For the Balance Sheets and Statement of Cash Flows, all highly liquid investments with maturity of 90 days or less are considered to be cash equivalents. The Company had a cash balance of $17,143 and $57,453 as of March 31, 2017 and December 31, 2016, respectively. At times such cash balances may be in excess of the FDIC limit of $250,000.
EARNINGS PER SHARE

The Company has adopted the FASB ASC Topic 260 regarding earnings / loss per share, which provides for calculation of “basic” and “diluted” earnings / loss per share. Basic earnings / loss per share includes no dilution and is computed by dividing net income / loss available to common shareholders by the weighted average common shares outstanding for the period. Diluted earnings / loss per share reflect the potential dilution of securities that could share in the earnings of an entity similar to fully diluted earnings / loss per share.

 

Other than the Notes Payable specified under Note 4 and Note 5 below, there were no potentially dilutive instruments outstanding during the interim period ended March 31, 2017 or the year ended December 31, 2016.
INCOME TAXES

The Company follows the asset and liability method of accounting for deferred income taxes. The asset and liability method requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between financial accounting and tax bases of assets and liabilities. The Company accounts for income taxes pursuant to ASC 740. There was no increase in liabilities for unrecognized tax benefits as a result of this implementation. The Company recognizes
FOREIGN CURRENCY

The U.S. dollar is the functional currency of the Company which is operating in the United States. The functional currency for the Company's Canadian subsidiary is the Canadian dollar. The Company translates its Canadian subsidiary's financial statements into U.S. dollars as follows:

 

● Assets and liabilities are translated at the exchange rate in effect as of the financial statement date.

 

● Income statement accounts are translated using the weighted average exchange rate for the period.

 

The Company includes translation adjustments from currency exchange and the effect of exchange rate changes on intercompany transactions of a long-term investment nature as a separate component of shareholders’ equity. There are currently no transactions of a long-term investment nature, nor any gains or losses from non-U.S. currency transactions.
REVENUE RECOGNITION

Since inception, the Company has been focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Following its recent entry into the generic pharmaceuticals business, the Company has become a fully integrated pharmaceutical company offering generic and proprietary drugs for the treatment of cancer and other acute and chronic indications. The Company intends to recognize revenues from the sales of generic pharmaceuticals, if or when they occur, at the time the products are sold and collectability is assured. In the event the Company provides consulting services in the future, revenues from such services will be recognized when the services are rendered and invoiced.
GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Since inception, the Company has had recurring operating losses and negative operating cash flows. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company’s continuation as a going concern is dependent on its ability to obtain additional financing to fund operations, implement its business model, and ultimately, attain profitable operations. The Company will need to secure additional funds through various means, including equity and debt financing or any similar financing. There can be no assurance that the Company will be able to obtain additional equity or debt financing, if and when needed, on terms acceptable to the Company, or at all. Any additional equity or debt financing may involve substantial dilution to the Company’s stockholders, restrictive covenants or high interest costs. The Company’s long-term liquidity also depends upon its ability to generate revenues and achieve profitability.

 

The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Summary Of Significant Accounting Policies Details Narrative    
Cash and cash equivalents $ 17,143 $ 57,453
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
4. Notes Payable (Details Narrative) - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Notes to Financial Statements    
Interest accrued $ 1,171 $ 9,011
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
6. Issuance of Common Stock (Details Narrative) - $ / shares
 3 Months Ended
Mar. 31, 2017
Dec. 31, 2016
Issuance of Common Stock    
Shares issued 48,428,125  
Par value of common stock $ 0.001 $ 0.001
EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 11 110 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://sunshinebiopharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheet (Unaudited) Sheet http://sunshinebiopharma.com/role/BalanceSheet Balance Sheet (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Balance Sheet (Parenthetical) Sheet http://sunshinebiopharma.com/role/BalanceSheetParenthetical Balance Sheet (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Unaudited Statement Of Operations and Comprehensive Loss Sheet http://sunshinebiopharma.com/role/UnauditedStatementOfOperationsAndComprehensiveLoss Unaudited Statement Of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Unaudited Statement Of Cash Flows Sheet http://sunshinebiopharma.com/role/UnauditedStatementOfCashFlows Unaudited Statement Of Cash Flows Statements 5 false false R6.htm 00000006 - Disclosure - 1. Descriptions of Business Sheet http://sunshinebiopharma.com/role/DescriptionsOfBusiness 1. Descriptions of Business Notes 6 false false R7.htm 00000007 - Disclosure - 2. Summary of Significant Accounting Policies Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies 2. Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - 3. Unaudited Financial Information Sheet http://sunshinebiopharma.com/role/UnauditedFinancialInformation 3. Unaudited Financial Information Notes 8 false false R9.htm 00000009 - Disclosure - 4. Notes Payable Notes http://sunshinebiopharma.com/role/NotesPayable 4. Notes Payable Notes 9 false false R10.htm 00000010 - Disclosure - 5. Notes Payable Related Party Notes http://sunshinebiopharma.com/role/NotesPayableRelatedParty 5. Notes Payable Related Party Notes 10 false false R11.htm 00000011 - Disclosure - 6. Issuance of Common Stock Sheet http://sunshinebiopharma.com/role/IssuanceOfCommonStock 6. Issuance of Common Stock Notes 11 false false R12.htm 00000012 - Disclosure - 7. Earnings (Loss) per Share Sheet http://sunshinebiopharma.com/role/EarningsLossPerShare 7. Earnings (Loss) per Share Notes 12 false false R13.htm 00000013 - Disclosure - 8. Generic Drugs License Sheet http://sunshinebiopharma.com/role/GenericDrugsLicense 8. Generic Drugs License Notes 13 false false R14.htm 00000014 - Disclosure - 9. Financial Statements Sheet http://sunshinebiopharma.com/role/FinancialStatements 9. Financial Statements Notes 14 false false R15.htm 00000015 - Disclosure - 10. Income Taxes Sheet http://sunshinebiopharma.com/role/IncomeTaxes 10. Income Taxes Notes 15 false false R16.htm 00000016 - Disclosure - 11. Royalties Payable Sheet http://sunshinebiopharma.com/role/RoyaltiesPayable 11. Royalties Payable Notes 16 false false R17.htm 00000017 - Disclosure - 12. Related Party Transactions Sheet http://sunshinebiopharma.com/role/RelatedPartyTransactions 12. Related Party Transactions Notes 17 false false R18.htm 00000018 - Disclosure - 13. Subsequent Events Sheet http://sunshinebiopharma.com/role/SubsequentEvents 13. Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. Summary of Significant Accounting Policies (Policies) Policies http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) Sheet http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative 2. Summary of Significant Accounting Policies (Details Narrative) Details http://sunshinebiopharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies 20 false false R21.htm 00000021 - Disclosure - 4. Notes Payable (Details Narrative) Notes http://sunshinebiopharma.com/role/NotesPayableDetailsNarrative 4. Notes Payable (Details Narrative) Details http://sunshinebiopharma.com/role/NotesPayable 21 false false R22.htm 00000022 - Disclosure - 6. Issuance of Common Stock (Details Narrative) Sheet http://sunshinebiopharma.com/role/IssuanceOfCommonStockDetailsNarrative 6. Issuance of Common Stock (Details Narrative) Details http://sunshinebiopharma.com/role/IssuanceOfCommonStock 22 false false All Reports Book All Reports sbfm-20170331.xml sbfm-20170331.xsd sbfm-20170331_cal.xml sbfm-20170331_def.xml sbfm-20170331_lab.xml sbfm-20170331_pre.xml true true ZIP 43 0001654954-17-004568-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-17-004568-xbrl.zip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ⅅ+C:@SM%[2=M5+OJM.NL7TQNK4 M#7/VK5*,'99:Y3DK-G*H(G4H2]H*6UWC0!*VB, ME;P;$JRJ NP%2E[;2")@E^)&(Z9O#0#9R%6-!LE7T5_?0,3&ZK8-D-3R.E:V M1@TMR+(F)3)^W;0/:':O: U&5.5);AG#MTS%=(W\"T(ODCBAJ'C]! 0BM"MSU>0&0%9/7S85F>OQK&4E MO^%=+;]AVV_IT^G<>>XZ?:ZETKF3]F[R]A_/_=NRJPX_"0E,AM'<@(_ -0H3 M])40/Y(6D6EO;3CBK<"A'CZ3"&S'O)H]9AWP^+N_Q&'Z_ Q_9^ . M3!<]TT-.4R]V@'E#R1Q%49H0?H%DU]Z:+4V'I'45WBC3U"JY';B4C[QJ)UUB MB*1$IF/)_= "Z&.DRU7;S+13MLHG0=R^V^=-6UN:C@)W5+M0'IN,Y HM5+-6 MJ8GI$&\_ VC(:@D$V0/"IR2252NKMC(=N.T)1(O$(TT]T_DYL\;,2*K49F/3L>K>2A;);\;LNJ5I,=T-Y3=XV"[%4#1/G=-NY**1%5D!D/KQ*+,6]M#,79-A=()M/;P/::A*0J M'3B&!R U7H:Q'^Y@Y=@Q3U\0BO BS&H^>1NVPH018Y+I^BM;7D[0G/U>6BH! MW('Q6HUP9$@W"6W"M:ADJ%QO&PV-5VWLBI- 9/W9]E,VVX9HP1-U^LRW M^2 MCYL+)G;!,1MA"S;!A*AUD>0D4@KP>8'\ A8_G@F,"1'^T(M"OR2C6\>D<4Q9#P0JT9%$]+3_1:A7[M2!9ERXJ$^!,W MPIX844%SXT5?^R$K58(=:^[?F2?\P"_0LO7#7:#KA%^JG\X;*;T*_#2[,5Y; MMA^NG91F!]Y=9MCOAQ:4GAUPCN7RC'O4+*B_*0FGIB>T2C(H"K8=E<"DL\E. MOH44N0&_'52XP].P%C<\0Q2O4^EY;BX@LMJG3W,%AK6P(X,);--@:)%<77)8 M2@2%<_BSL!YP M1@!UY#;#YU%KWA3ZYZH"24QB:$3&P[=1 =_BRD!Z+:4O9T M(=O+JUAUE8N_*7\1D$?!K:WWL%M;O!23T<( JPMZ3P2Q]G&\S?6^PPV0PIMKMF"[D MV3=%P=W8/KN MY N.)$VECA1)3:M09$5@V-"^<3=<]B+!2!!&5="8OHCY$A@"UDL!S%BY# M)DK">3Q#;'BY$9(GT6V'J9+4]'W/%S5:H"+MP?TYC25/8N&2%Q*PB2<)XXD< M?E@/IB^;OO HT%'K2\[=TWE^5"1*C%52F;[G:G3^;JKO]6_?F-[2::J8KB[# M&XI6+O8!V7XJ2M/W=5_0ZJ%J?(L#ANU(^8P6,2N1OW\%(#5^-]CHF!%HTH[] M0I/=8C^;LROU\F#4QF\4&X5?K$\[1@ \:CO$J8(%=Y-?<#3HZ_:U)ZD*)+YD M&^9HH+,J:5_&;T0/=UH%T)D=,TB^D696<^S]EF"*F"1^PIG.7Y410PP@-7[7 MN0<\1%?8M[*?A.ML"/.WX>+T4(-$7W-O=,G(2^0-LF1(^S)^-7BX)0.@,TN6 M#$H\A/R(7VZ^)C%2NYEB"O-W2;N#T2A")=7*2%%%_E7Y-W'.[PG[AR*D*")\/D=>>M[H/;CA MVR;?\T MY(*(49;1&+_R.QBF:LW8@: <*SU4['='!/K7FW-7J6$R%Y?&=LR\N230(AN>A!8'%NV2URLIEN4$1++D,YX0N,WC4MWR@'4!'P8COUFJ'A32U M8\>D6LK*.4LH&][96IX^_EE/3*87U'HC M][$M(1B0,@G/ GXWWO')4$B(E3(2)E?$#8LX%S3RKJ"!HC'> \7=T0"IPXY% MZSFI"TN>D:ZV@D(SWMW)7DM*F\BV@,'SMN[=)WY@)L>CUA *R7@O"?>$I%7P M%E2,59HX0Y%'\2I]QW0#< MLS%W$DA/Q(;_)L.U+@8=6_775D:"Q:;IYBY9+EVZF<[O\"+$<^RY89SGWW,G MB(GLE1V;++(;9VH[:12VM^T&^+'NB$>[97*36W[<P M'?@U<2ES'8)-VP@ V#24_@TOW7HJM,G\6],8*];^J6[M[_:.]S7C M> M/FPR@19_J]T$WM5-X-->*1Q7HAYPF.F[ZK;ZZ*>$@<-&A=_"(&!] )*;M!A] MQUU+)S;93.GHO=U6WC<.LP^8CY)2.1F9!0D3SPRJ/10ID0W9'UKNB9S*L$<" MP$>4"?)*EIQ;LG$#GFLJ"PU/F@DADSUG2_K[B \+&*TK$+[U E$:#WII18'! M8EEH"*40<*FTO&!1::0H3 [WJA%@I]*)N5E9))=ZG5%3&EQL1,QIK3U:G1A> MBJ XUM:C#GJRR2KODEF$?DM8O^=KL3O4R%.8'/&,H8+4R6G?]/(TU*V^JKXA M\64QR>M:O-3RV&@?D#0[:;K=I''NKY5NY_Q0_/3C?S+O!HI./*>LI)Q)ST^? M_7<)U6O+LH/HP(XK#]\B-)V?1S%>LNE%<@NRWL[T$W':D+0+:@<(@DHD8-N! MD9M^<4W?BG348@>2]1,K,(9*0N,/I>FB!U2%';AMPUY@P,04QA\BTT5*);P= M$(F?SXO8))'^,TAU#)\X>W1I_*4R79![J\^.47"+F%.3(%YMGVWKM;:8 %+C MSY'IH@I6AQWHE1\N9#\'*$]K+S]B",:S4V?&GQK31;B'RNS G,&K?3JWS6H_C4\;EAC&?U@C2]5H; MY"9CL,,@#O)J!6JSR=++=PA@]MS(KJ_?R!K;9-_J,4?M*;!L4R]-N6EO_RH/ M..3"=ZY-N49T1B)4JTQIUR46F-DU$N\EEUH&L\#?^467$DC7R7*&*%LT>-2+ M39@TG='9E#^-'Q!]!@9PQ-.OUU=R'68(U5GBZK072\RD2460N#@ 6M.'+H,@ M!:HOV:(R.R NJ8 )/:7IJI65PZS?AI*:LYC8]#'-""!K*.W-+-_/:=VP1;MQ M*XBGJ);3O,?>*TLX5FR6090FRX@5KZ3RJV>IFS4G]-&EON2\6T9CL@5*] M:I=2"W;,L&>YU3,9L\\JB9&%;]GHPE1/3#N*O*M"*!^6_X'S,W M0NR3?P-02P$"% ,4 " E?:Q*1,-JW%8M !\0 $ $0 M@ $ &UL4$L! A0#% @ )7VL2H9EG1\&" $$@ M !4 ( !AD$ '-B9FTM,C Q-S S,S%?9&5F+GAM;%!+ 0(4 M Q0 ( "5]K$IE(&2.]R +.V 0 5 " ;]) !S8F9M M+3(P,3&UL4$L%!@ 0 & 8 B@$ )*! $! end